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Det var den draumen om at 
 berget skal opna seg  
kjelder skal springa 
Det var den draumen om å  
gli inn på ein våg me ikkje har visst om 
 
Det var den draumen som gav  
ein dråpe sannkjenning i 
fløande hav av eiga røynsle  
 
Det står einkvar fritt 
å drøyme og 
å freiste 
   (Hege Kersten 2012, inspirert av Olav O Hauge/Valkyrien Allstars og Arthur Arntzen) 
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SUMMARY  
Background: Evidence-based knowledge of drug safety in geriatric patients with 
polypharmacy is limited, but the focus on risk assessment tools is increasing. The risks 
related to pharmacological treatment are often assessed by the number of inappropriate 
drug prescriptions. Anticholinergic drugs display a high risk of adverse effects and are 
denoted as inappropriate in elderly people. The overall objective of this thesis was to 
achieve better clinical understanding of the risks related to anticholinergic drugs in frail 
elderly patients.   
 
Anticholinergic drugs are prescribed to treat a variety of medical conditions such as 
psychotic disorders, depression, sleeping disorders, and urinary incontinence. Despite that 
the overall use of anticholinergic drugs has decreased over the past decades, drugs used to 
treat urinary incontinence will become increasingly prevalent as the elderly population 
increases. Anticholinergic drugs acts towards muscarinic receptors in the central and 
peripheral nervous system and inhibit acetylcholine mediated responses through 
competitive receptor binding. Anticholinergic adverse effects are caused by the unselective 
muscarinic antagonism and give symptoms that are easily misinterpreted as age-related 
complaints, e.g. dry mouth, constipation and reduced memory. Many drugs have shown 
competitive binding activity towards muscarinic rat brain receptors in vitro and have 
potential anticholinergic activity (AA) in vivo. The AA of drugs is previously rated with an 
ordinal 4-point scale, and the sum of each drugs’ AA score expresses the overall 
anticholinergic burden of a patient. A high anticholinergic drug scale (ADS) score has been 
associated with increased risk of cognitive and functional impairments in many observational 
studies. However, little is known about the pharmacodynamic interactions between 
potentially anticholinergic drugs used concurrently. There is also a lack of evidence-based 
knowledge of the clinical effects of a reduced anticholinergic burden. Four studies are 
included in this thesis: one in vitro study, two clinical studies with cross-sectional design, and 
one randomized control trial (ClinicalTrials.gov; NCT00854438). All studies were targeted to 
gain knowledge of anticholinergic drug safety. 
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Methods: We developed and validated a high-throughput version of the published radio 
receptor bioassay used for determination of the AA of individual drugs. The method is 
described in the in vitro study, but was also used to measure AA in the patients’ serum in the 
three clinical studies.  In the in vitro study, we used the bioassay to compare the potential 
risk of central anticholinergic adverse effects between five urinary spasmolytic drugs (USDs) 
used to treat the symptoms of overactive bladder.  
 
We conducted a single-blinded randomized controlled trial in order to investigate the clinical 
effects of a reduced anticholinergic burden in nursing home residents with an ADS score ≥ 3 
and no severe dementia. The participants were recruited from 22 nursing homes and 
randomly allocated (1:1) to intervention or control. The intervention was a pharmacist-
initiated reduction of ADS score after multidisciplinary drug reviews. Primary end-point was 
the CERAD-10 wordlist test for immediate recall. Secondary end-points were MMSE, delayed 
recall and recognition of words (CERAD), saliva flow and serum anticholinergic activity. The 
participants were re-tested after 4 and 8 weeks, and the study groups were compared after 
adjusting for baseline differences. At baseline we sampled blood for pharmacogenetic 
analyses of hepatic enzymes involved in the metabolism of anticholinergic drugs.  The 
baseline data were used to investigate whether patients’ serum AA were related to their 
genotype-determined activity in the drug-metabolising CYP2D6/2C19 enzymes.  We also 
used the baseline data to evaluate the additive properties of the ADS score model by 
investigating whether increasing ADS scores above 3 were associated with a gradual decline 
in cognitive function.  
 
Findings: In our in vitro-based risk assessment of the five USDs marketed in Norway, we 
found that darifenacine had the lowest potential for central anticholinergic side-effects, 
while the active metabolite of the prodrug fesoterodine, 5-HMT, and tolterodine were 
shown to have the highest detectable AA.   
The cross-sectional evaluation of the ADS score model did not support a progressive decline 
in cognitive function with ADS score above 3.  However, ADS scores above 5 were associated 
with reduced saliva flow and elevated AA in serum.  
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The interventional study showed that the pharmacist-initiated drug changes significantly 
reduced the patients’ ADS scores with two units, whereas the score remained unchanged in 
the control group. This reduction did not translate into significant improvements of cognitive 
function or peripheral anticholinergic symptoms compared to the control group.   
The preliminary findings from the genotyping suggested that elderly poor metabolizers of 
CYP2D6/2C19 are at higher risk of elevated serum AA than extensive metabolizers. Whether 
poor metabolizers are more prone to experience adverse anticholinergic effects, needs to be 
further studied in larger patient samples. 
 
Conclusion: There are many determinants of the central anticholinergic drug response and 
the anticholinergic burden in the brain is difficult to predict in elderly patients using multiple 
drugs. The clinical utility of the anticholinergic risk assessment tools might be limited by the 
simplification of complex pharmacological mechanisms into compulsive categories without 
considering the high intra-individual differences in drug response in elderly people.  
Our findings need to be confirmed in larger study samples, and there is a general need for 
more interventional studies in pharmacological geriatric research.  
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INTRODUCTION 
 
A DRUG CRESCENDO  
Never before have physicians had such an abundance of prescribing options, and elderly 
people are taking more medications than ever. The use of medications among the elderly is 
disproportionate in relation to their population share. In Norway, people above 65 years 
comprise only 15% of the population, but use approximately 50% of all prescribed drugs (1). 
The population share of elderly (≥ 65 years) is growing faster than any other age segments, 
and the number of people above 80 years increases most rapidly. 4.5% (221 000) of the 
Norwegian population are 80 years or older and the number is expected to double within 
the next 30 years (2). Old age is accompanied by an increased likelihood of illness and 
several chronic diseases indicate prescription of multiple medications. Furthermore, the 
availability and use of drugs to prevent, treat, or relieve pathological or age-related 
complaints continue to rise. A Finnish cohort study of medicine use among the elderly 
reported that the prevalence of older people using more than 5 medicines had increased to 
67% from 1998 to 2003 and the proportion using 10 or more medications had increased to 
28% (3). Accordingly, a rapid increment in the prevalence of older people receiving multiple 
concomitant drugs is seen in Norway and other countries (2,4,5). As the population is aging 
and the number of drugs taken by aged people still increases, a crescendo in the drug 
market can be expected over the next decades.  
 
POLYPHARMACY  
Various terms are used to define polypharmacy in the literature. Commonly, polypharmacy 
is defined either in terms of inappropriate medication intake e.g. “the administration of 
more medicines than  clinically indicated, representing unnecessary drug use” (6), or 
according to the number of concomitant medication used, e.g. the use of five or more 
medications concurrently (7). An increasing number of drugs taken daily is associated with a 
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number of negative health outcomes, but on the other hand prescribing of multiple 
medications may be required to achieve appropriate treatment of many chronic medical 
conditions. To ensure that under-treatment is not neglected in the elderly, it is important to 
look beyond a simple medication count when evaluating the drug therapy. A commonly used 
quality indicator of appropriate polypharmacy is drug related problems (DRP)s (8).  A DRP is 
defined by the Pharmaceutical Care Network Europe, as «an event or circumstance involving 
drug therapy that actually or potentially interferes with desired health outcomes» (9). The 
definition of DRPs encompasses potentially and manifested problems caused by 
inappropriate prescriptions, unnecessary drug-use and under-treatment. It has been shown 
that the number of DRPs such as adverse drug reactions (ADR), unfavorable drug-drug 
interactions and poor adherence to the drug regimes, increases approximately linearly with 
the number of drugs used (10,11). Interestingly, it has also been shown that in geriatric 
patients receiving more than five drugs concurrently, the probability of under-prescription 
increased significantly with the number of drugs prescribed (12). For the purpose of this 
thesis, polypharmacy is discussed according to the definition of concomitant use of five or 
more medications.  
 
POLYPHARMACY IN THE ELDERLY 
The etiology of polypharmacy in the elderly is multifactorial. Application of disease-specific 
prescription guidelines to older patients diagnosed with several chronic medical conditions 
might result in excessive polypharmacy. Additionally, older people are the major users of 
complementary and alternative medicines (13,14). Polypharmacy is of special concern in the 
elderly because older people are at higher risk for adverse drug events (ADEs) which are 
often more severe than in younger individuals. ADE is defined as an injury caused by the 
drug therapy ‒ and may result from adverse drug reactions (ADR) or medication errors. 
Between 5% and 10% of hospital admissions among older people are related to ADEs (15). 
Polypharmacy is associated with a significant decline in activity of daily living (ADL), 
increased risk of hospitalization, and mortality (16-19). It is also reported that polypharmacy 
represents a markedly increment in medical costs (20). Hence, reducing  unnecessary 
polypharmacy is an essential medication safety issue in the elderly and interventions 
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designed to improve appropriateness of multiple drug regimes in older people is of major 
importance (8) 
                                                                                                                                                                                                  
POLYPHARMACY IN NURSING HOMES  
Older people in long-term care are of increased risk of receiving multiple drug regimes and 
the prevalence of polypharmacy among nursing home residents is significantly higher 
compared with non-institutionalized elderly people (13). Norwegian nursing home residents 
are characterized by a mean age of 85 years and poor ADL function. Moreover, 80 % of the 
residents have dementia (21). The mean regular daily intake of drugs among Norwegian 
nursing home residents is 6-8 medications (22,23). This is in line with prevalence studies of 
polypharmacy among nursing home residents in other European countries (13). 
Polypharmacy in nursing homes is consistently associated with an increased number of 
potentially inappropriate drugs, negative health outcomes and  increased nursing time 
needed for medication administration (24). 
 
INAPPROPRIATE DRUG PRESCRIPTION  
The phrase “Inappropriate drug prescription (IDP)” is another term used to express the 
quality of drug regimens and encompass all prescriptions that are assumed to pose more risk 
than benefit, particularly when safer alternatives exist (25). IDP compass misprescribing such 
as suboptimal dose and/or duration of drug exposure, under-prescribing of beneficial drug 
treatments, and unnecessary drug use (26). Judging of appropriateness includes more than 
pharmacological rationalism; the patients’ preferences, the expectations of the relatives, the 
traditions for pharmacological treatment among the caregivers, and the social aspect which 
in its widest context embrace the attitude and tolerance for good health and disease. 
”Inappropriate drug prescription” is an elusive term, but as for other term indicators, it could 
be assessed with explicit (criterion-based) outcome measures or implicit (judgment-based) 
outcome measures (27). Explicit measures are usually drug-oriented and/or disease-oriented 
while implicit measures are usually based on information from the patient (26). Hence, the 
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explicit indicators of IDPs represent the evidence based perspective of the health care 
professionals while the implicit approach represents the individual view of disease and 
treatment. However, since evidence-based knowledge of efficacy and safety of drugs in 
older people is limited, the explicit criteria used to measure IDPs are commonly based on 
expert consensus. There are many lists of IDPs to elderly, but the most widely cited explicit 
tool is Beers’ criteria while Medication Appropriateness Index is the predominantly used 
implicit measure (25). According to consensus-based lists, the prevalence of IDPs among the 
elderly is reported to be high. In Norwegian nursing homes it has been reported that 76% of 
the patients had potentially drug-related problems due to IDPs (28). Two more recent 
studies in Norway have used the Norwegian General Practice  (NORGEP) criteria, which is a 
prescription tool based on Beer’s criteria  to assess IDPs in people aged 70 years or older 
(29). These studies reported that among elderly people acutely admitted to hospital, the 
number of IDPs increased from 24% to 35% during the hospital stay (30), and the number of 
IDPs among home-dwelling elderly was 35%, of which 65% was psychoactive medications 
(31). However, to be clinically relevant, the use of inappropriate prescription tools must 
translate into clinical outcomes relevant for geriatric patients. Relevant outcomes could be 
reduced rates of ADRs and falls, increased cognitive and physical function, and enhanced 
self-care capacity (32). Despite that consensus-based lists of IDPs in the elderly have been 
linked to a number of negative health outcomes in the literature, further studies in real-life 
settings are needed to test the clinical utility of such lists (26).  
 
DRUG SAFETY IN THE ELDERLY 
The safety and effectiveness of medications are thoroughly investigated in premarketing 
studies during the drug development process. The determination of drug dosage and the 
prediction of the risks and benefits of every new drug launched are based on the evidence 
from the premarketing trials. Post marketing randomized controlled trials (RCTs) are 
essential to evaluate the safety and efficacy of drugs in the target population. The very 
elderly population (≥ 80 years old) is mainly excluded from both the premarketing and post 
marketing RCTs and there is a discrepancy between the prevalence of elderly among the 
investigated population and the population actually receiving the medications (33). It is a 
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paradox that the underrepresentation of older patients in clinical trials occurs for the same 
reasons that cause the risk:benefit ratio of the drug treatment to differ greatly from that in 
adults as a whole. Frequently used exclusion criteria are existing disease characteristics, the 
use of concomitant medications, frailty and advanced age per se (34,35). In parallel, reduced 
homeostatic control, multiple comorbidities, and functional and cognitive status are all 
determinants of the overall risk:benefit ratio of multiple drug therapies and provide 
uncertainty to the extrapolation of results from younger and/or healthier adults to older 
adults. Hence, there is a gap in evidence based information regarding the overall effects of 
multiple medication exposure to older people with multiple illnesses. To fill the gap between 
evidence based knowledge and prescribing practice in the elderly, the regulatory authorities 
have encouraged the inclusion of older people in RCTs for the last 15 years, but data from 
such studies remain very scarce (36).  
 
AGE-RELATED DIFFERENCES IN DRUG RESPONSE  
The progress of aging is a heterogeneous and an individual multifactorial process depending 
on exposure to intrinsic and extrinsic factors over time. Accumulation of deficits in multiple 
organ systems and regulatory processes affect pharmacological features and homeostatic 
control at different rates and results in a greater variability in drug response in aged versus 
younger adults. Furthermore, patophysiological changes that occur in diseases that are 
common in advanced age provide additionally diversity in older people’s drug response. The 
debility in compensation mechanisms to regain homeostasis after drug exposure and the 
general decline in physiological reserves in geriatric patients result in increased sensitivity to 
certain drugs and poorer recovery from ADEs.   
 
PHARMACOKINETIC CHANGES  
The aging process affects pharmacokinetic processes that alter the serum concentration of 
different drugs. Reduction in active transport mechanisms and first-pass metabolism might 
change the bioavailability of some drugs. Major changes in body composition with a relative 
increase in body fat, enlarges the distribution volume of lipid soluble drug, whereas the 
reduction in plasma protein concentration increases the free fraction of active drugs which 
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might be of clinical relevance for drugs with a high degree of protein binding. Yet, the most 
important factor for dose adjustments in elderly people is the age-related reduction in drug 
clearance that leads to prolonged elimination half-life of several drugs (32). This is mainly 
due to reduced renal excretion caused by lowered glomerular filtration rate (GFR), but age-
related alterations in hepatic metabolism, foremost reduced liver size and hepatic blood 
flow might also prolong the drug elimination half life (37). The implication of renal and 
hepatic aging on drug clearance depends on the pharmacokinetic profile of the drugs (38). 
  
PHARMACODYNAMIC CHANGES 
Age-related pharmacodynamic changes are related to effectors’ system function and may be 
explained by changes in physiological factors, receptor abundance, receptor affinity and post 
receptor responses, or intracellular signaling pathways. Pharmacodynamic changes influence 
the end-organ responses, tend to be drug-specific and for the most part the mechanisms of 
the age-related differences are not well defined (35). The aging process may result in both 
decreased and increased post receptor responses to drug exposure which in turn influence 
the sensitivity to drug dosage. For example, older people have shown decreased sensitivity 
for beta adrenergic receptor agonists and antagonists while the sensitivity for drug effects 
such as sedation with benzodiazepines and cognitive impairments with anticholinergics are 
increased (39,40).   
 
ADVERSE DRUG REACTIONS (ADR) 
The World Health Organization has defined ADRs as harmful, unintended reactions to 
medicines that occur at doses normally used for treatment. The risk of ADRs is a very 
important measure of medication exposure in the elderly because ADRs often have more 
serious outcomes in older than in younger adults (41). A meta-analysis has shown that the 
odds for elderly people to be hospitalized of ADR is 4 times higher than for younger ones, 
that is 16.6 % versus 4.1% (41). It has also been shown that most of these hospital 
admissions are avoidable, meaning that an intervention by a caregiver could have prevented 
the admission (42). ADRs are among the leading causes of death in many countries (43). In 
Norway, 18 % of the deaths in a medical department of a major hospital have been related 
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to one or more medications, and the fatal ADRs were significantly associated to age, multiple 
diseases and polypharmacy (44).  
 
APPROACHES TO IMPROVE DRUG SAFETY  
 
MULTIDISCIPLINARY DRUG REVIEWS 
Prescription of medicines is a predominant part of geriatric health care and should not be 
viewed as a solitary activity undertaken by physicians (26). A collaborative approach to 
prescription, involving a clinical pharmacist in structured medication reviews within the 
context of geriatric evaluation and management units, have shown to improve the 
appropriate use of medicines (45). A medication review is defined by the National 
Prescribing Center in UK as a “structured critical examination of the patient medicines with 
the objective of reaching agreement with the patient about the continued appropriateness of 
the treatment, optimizing the impact of medicines, minimizing the number of medication-
related problems and reducing waste” (46). The objective of medication reviews includes  
both pharmacological rationalism and the patients’ preferences and is an advocated method 
to optimize drug therapy (47).  
Many studies report that clinical pharmacists identify a large amount of drug related 
problems (DRPs) and contribute to prevent DRPs like adverse drug reactions, drug-drug 
interactions and unnecessary drug use (48,49). It has also been reported that clinical 
pharmacists’ interventions improve compliance, reduce polypharmacy, and increase 
prescription quality (50-53). An RCT in patients 80 years or older in Sweden reported a 
significant reduction in hospital re-admissions and net cost per patient in the intervention 
group that received pharmaceutical care at ward level throughout their hospital stay (54). 
Reviews of pharmacist interventions have concluded that pharmaceutical care appear to 
improve appropriate polypharmacy in older people in terms of reducing IPs and DRPs, but 
multicenter studies with larger sample sizes and reproducible interventions are needed to 
measure the effects on patient-related health outcomes (8). However, the health authorities 
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in different countries have recently emphasized clinical pharmacists as essential resources to 
improve medication safety in elderly people and reduce unnecessary health costs (49,50).  
 
CLINICAL PHARMACY IN NURSING HOMES  
Nursing homes encompass approximately 40 000 beds and are the largest health 
institutional level in Norway (22,55). Nursing home residents are characterized by multiple 
chronic diseases and functional and cognitive impairments for which multiple medications 
are prescribed. About 70 % of the residents are women and the mean age is 86 years (56). It 
is reported that almost 80 % of residents in nursing home care have dementia and 90 % have 
one or more neuropsychiatric symptoms which is a group of psychological symptoms such as 
depression, hallucinations, apathy and anxiety (56,57). In order to provide good medical care 
and services to this complex patient group, multifaceted approaches like involvement of 
nurses and care givers in treatment strategies, educational training in geriatrics, continuance 
in the physician staffing and interaction with clinical pharmacists in the prescribing and 
evaluation of medication treatment have been suggested (23,26). Although interaction by 
clinical pharmacists at the time of prescribing is not always feasible in Norwegian nursing 
homes, studies have reported that the involvement of clinical pharmacists in regularly 
multidisciplinary medication reviews improved quality of drug prescribing in nursing homes 
(28,58). Still, clinical pharmacists are almost absent in nursing homes and in the community 
health services in Norway.    
 
REDUCED POLYPHARMACY    
Due to the increased risk of DRPs associated with polypharmacy, it is likely to expect that 
elderly people would benefit from drug withdrawal in general. Furthermore, reduced 
polypharmacy increases patient adherence to drug regimes which is essential to achieve 
maximum benefit and minimized ADE (11). However, withdrawal of medications might be 
difficult to implement and is not always beneficial in elderly patients. Discontinuing a drug is 
a multidimensional action that involves many parts in addition to the prescribing physician. 
That is, the patient, the relatives and the care-givers. Drug withdrawal is an active 
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pharmacological intervention that needs the same attention and monitoring as prescription 
of a new drug and certain drugs need to be tapered off over time to avoid withdrawal 
symptoms and rebound syndromes. This is of particularly importance in frail elderly people 
with diminished regulatory responses and reduced capacity to regain homeostatic control 
after drug changes. However, there have been reported that reduced polypharmacy have 
increased patient satisfaction without any clinical consequences (59-61). Furthermore, there 
are several trials reporting beneficial effects in older people after reduced exposure to 
certain classes of medicines, i.e. withdrawal of psychotropic medications are shown to 
reduce incidence of falls (62). On the opposite, a recent RCT that discontinued 
antidepressants in Norwegian nursing home residents with dementia and neuropsychiatric 
symptoms, reported that the drug withdrawal was unfavorable leading to increasing 
symptoms in a subgroup of the discontinued patients after 25 weeks (63). The result 
contradicted with previous cross-sectional efficacy studies and highlights the needs for more 
RCT studies conducted in real-life setting to increase evidence-based guidance to what drugs 
should be continued and what could safely be withdrawn in nursing home patients.  
 
GENOTYPING  
The aging process affects organs and compensatory mechanisms with great interindividual 
differences and this amplifies the differences in drug response between older individuals. 
Other determinants of interindividual drug responses are inherited and are thought to be 
stable throughout the lifetime. Sequence variations in the genes encoding for hepatic drug 
metabolizing enzymes are of major importance for the variations in drug response (64), but  
inherited differences in hepatic drug metabolism phenotype might be a consequence of 
other factors than changes in the DNA sequence (epigenetic).The possible impact of 
epigenetics on drug clearance is an upcoming research area of great interest and is likely to 
be of special importance for the treatment outcome in aged people who are exposed to 
environmental factors over many years (38).  The influence of aging and genetic variability 
on hepatic drug clearance and secondarily on the serum concentration of drugs, adverse 
drug effects, and therapeutic outcomes, depends on many factors including the 
pharmacokinetic profile of the drugs. Many lipophilic drugs, including anticholinergics, are 
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metabolized by the hepatic cytochrome P450 2D6 and 2C19 enzymes before renal excretion. 
These enzymes are highly polymorphic and carriers of variant alleles encoding deficient 
enzyme activity in CYP2D6 or CYP2C19 is phenotypically classified as poor metabolizers 
(PMs). The prevalence of CYP2D6 PMs are 5-10 % in Caucasians, while 2-3 % of Caucasians 
are CYP2C19 PMs. Compared to patients carrying functional alleles, i.e. extensive 
metabolizers (EMs), PMs are at risk of concentration dependent adverse drug reactions and 
drug-drug interactions (65). An age-related increase in pharmacodynamic sensitivity and the 
narrow therapeutic range of some anticholinergic drugs such as tricyclic antidepressants, 
emphasize the need for specific anticholinergic dose recommendation for elderly people. 
Nevertheless, genotyping have the potential to identify patients with increased risk of 
anticholinergic toxicity and might guide the physician to prescribe a non-anticholinergic drug 
alternative or reduce the anticholinergic dosage and thereby increase drug safety in elderly.  
 
ANTICHOLINERGIC DRUGS 
 
HISTORY AND USE 
Anticholinergic agents occur naturally as alkaloids in Atropa belladonna and other plants in 
the Solanaceae family, native to Europe, North Africa and Western Asia. Belladonna alkaloids 
and their synthetic analogs have been used for their cosmetic, therapeutic, and toxic effects 
throughout centuries. Extract from Atropa belladonna was used as poison-tipped arrows 
thousands of years ago and the ancient Romans used it to murder contemporaries. The term 
belladonna refers to the beautiful Italian women who desired dilated pupils to appear more 
seductive. In modern times, synthesized anticholinergic drugs have been used for a variety 
of medical conditions such as parkinsonism, depression, urinary incontinence, allergy, travel 
sickness, obstructive lung diseases, sleep disorders, peptic ulcer disease, cardiac arrhythmias 
and psychoses among others. As late as in the 1950s, atropine induced coma was used as a 
treatment for psychosis (66). In 1991 there were as many as 600 drugs with anticholinergic 
activity on the United States market (67). Currently, many of these drugs are withdrawn, but 
a high number of drugs with potential anticholinergic properties are still present on the 
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market (68). As a consequence of increased knowledge about the high risk of anticholinergic 
side-effects and the development of non-anticholinergic drug alternatives, the use of 
anticholinergic medications have declined over the past decades. Anticholinergic drugs are 
now considered as potential inappropriate drugs in the prescription appropriateness tools 
for elderly people (29,69,70). Still, such drugs are frequently prescribed for several 
indications and are the most common inappropriate drugs used in elderly people. 
Epidemiological studies have reported that 20-50 % of the elderly population use a 
medication with possible anticholinergic properties (71,72).  
 
RISK FACTORS ASSOCIATED WITH ANTICHOLINERGIC DRUG USE 
Risk factors for anticholinergic drug use are frequently present in the elderly and include 
polypharmacy, institutionalization, and the presence of certain medical conditions, e.g. 
urinary incontinence and dementia (24,73,74). Despite the anticholinergic hypersensitivity 
present in patients with dementia, studies have shown that elderly patients with dementia 
are more frequently exposed to definite anticholinergic drugs than those without dementia 
(73,75). It has also been shown, in four different epidemiological studies, that people using 
cholinesterase inhibitors have increased risk of receiving an anticholinergic drug with the 
potential to antagonize the effects of the cholinesterase inhibitor (75-78). This might be due 
to misinterpretation of the adverse effects of the cholinesterase inhibitor (77). Elderly 
people in nursing home care use significant more anticholinergic drugs than home-dwelling 
elderly (71,79). One study reported that 60 % of nursing home residents used 
anticholinergics, while the prevalence was 23% among the home-dwelling elderly, and 
among nursing home residents 10 % used several anticholinergic drugs concurrently (71). 
Furthermore, it has been reported that among hospitalized people above 65 years the 
prevalence of anticholinergic prescription increased significantly during their hospital stay 
(80). Finally it has been shown that within palliative care, the use of anticholinergic drugs 
increase as death approaches (81).  
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ANTICHOLINERGIC EFFECTS 
Acetylcholine was identified in 1914 and was the first neurotransmitter to be chemically 
isolated and characterized (82). Acetylcholine is synthesized in certain neurons by the 
enzyme choline acetyltransferase and mediates parasympathetic nerve impulses in the 
central and peripheral autonomic nervous systems. The enzyme acetylcholinesterase rapidly 
hydrolyses acetylcholine into its inactive form in the synaptic cleft. Acetylcholine acts on two 
different cholinergic receptors in the parasympathetic nerve system, that is nicotinic 
receptors which are ligand-gated ion channels located on autonomic ganglia and skeletal 
muscles, and transmembrane muscarinic G-protein coupled receptors located in the brain 
and in the heart and in smooth muscles innervated by autonomic effector cells. The 
peripheral and central anticholinergic effects of drugs are caused by the activity towards 
muscarinic receptors.. There is no nicotine receptor antagonists marketed in Norway, and 
drug-induced anticholinergic antagonism refers to inhibition of muscarinic effects. Hence, 
“antimuscarinic drugs” would be a more pharmacologically precise term, but in accordance 
with the terminology used in the literature, we use “anticholinergic” throughout this thesis. 
There are five subtypes of muscarinic receptors, M1, M2, M3, M4 and M5, that have been 
characterized by molecular cloning (83). The expression of the muscarinic subtypes in the 
cholinergic nerve system and the response of acetylcholine-mediated activation are 
overviewed in table 1. Muscarinic receptors are widely distributed throughout the human 
body and mediate distinct physiological responses according to location and receptor 
subtype (84). However, there is a potential interplay between the receptor subtypes 
responsible for the acetylcholine-mediated functional response. The M1 receptor, 
predominantly distributed in the brain, outnumbers the other receptor subtypes posing 40-
50 % of the total amount of muscarinic receptors (84). The M3 receptor is the predominant 
receptor in the peripheral nerve system; distributed in smooth muscles and exocrine glands 
and activation mainly cause contraction and secretion respectively (84).  
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Table 1: Distribution of muscarinic receptor subtypes and acetylcholine-mediated responses 
Organ  Functionally 
predominant receptor(s) 
Acetylcholine-mediated response  
Brain M1 (M2, M4 and M5) Promote learning and memory processes, 
controls dopamine release 
Eyes M3 Contractility responses, tear production  
Mouth M1 and M3 Salivation  
Heart M2 Modulation of contraction and atrio-
ventricular conduction, slows heart beat  
Lungs M3 Constricts bronchi 
Gastrointestinal 
tract  
M2 and M3 Promote acid secretion contractility and 
mobility 
Liver M3 Stimulates release of bile-acids 
Blood vessels M3 Vasodilation  
Sweat glands M3 Sweat secretion  
Bladder M2 and M3 Detrusor contraction  
 
 
ANTICHOLINERGIC ADVERSE EFFECTS 
Anticholinergic adverse effects are caused by the drugs’ unselective antagonism of 
muscarinic receptor subtypes and the symptoms are related to the inhibition of 
acetylcholine-mediated responses. The symptoms may be dramatic, but are more often 
subtle and easily discounted as natural consequences of aging, leading to prescription of 
symptom-relieving drugs rather than adjustment of the responsible drug(s) (85).  
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PERIPHERAL ANTICHOLINERGIC ADVERSE EFFECTS 
Peripheral anticholinergic adverse effects are related to the inhibition of acetylcholin-
mediated muscle contraction and secretion. Symptoms of peripheral adverse effects range 
from mild reduction in salivary flow to fatal heatstroke caused by the inhibition of sweating 
and peripheral vasodilatation (86). But even the most common peripheral anticholinergic 
complaint, dry mouth, may affect important aspects of life such as speaking, the enjoyment 
and ingestion of food (and thus an adequate nutrition), and wearing of dental prostheses 
(87). A reduction in saliva flow increases the susceptibility to oral infections and caries, and 
many elderly people describe great discomfort related to xerostomia. There are many 
antimuscarinic side-effects in the eyes i.e. dilation of the pupils, increased intraocular 
pressure, dry eyes and blurred vision. Visual disturbances might lead to serious outcomes in 
elderly people such as falls and decreased function. Anticholinergic drugs can also induce 
tachycardia which is reported to have serious consequences in older people (82). Other 
common symptoms of peripheral anticholinergic adverse effects are urinary retention and 
constipation (87).  
 
CENTRAL ANTICHOLINERGIC ADVERSE EFFECTS  
The risk of central anticholinergic adverse effects is determined by the drugs’ distribution to 
the brain and their competitive binding affinity to muscarinic brain receptors. The 
concentration of the drugs within the brain is regulated by the balance between passive 
influx and active efflux across the blood-brain-barrier (BBB) (84). Factors that influence on 
the permeability across the BBB are contributing factors in the risk assessment of adverse 
central effects (84). Drug characteristics such as small molecular size, no polarity, and great 
lipophilicity enable passive influx through BBB, while the efflux is facilitated by the drugs’ 
specificity for the active transporter molecule permeability-glycoprotein (PgP). Moreover, 
the PgP-mediated efflux might be affected by genetic polymorphism and/or drug-induced 
inhibition of the transporter protein (84). As an example, anticholinergic drugs used to treat 
urinary incontinence show different propensity to cause central anticholinergic effects due 
to different molecular characteristics that affect the BBB penetration (84). Symptoms of 
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anticholinergic effects in the brain are linked to the inhibition of acetylcholine transmission  
in certain brain areas including the forebrain, cerebral cortex, hippocampus, and corpus 
striatum. Acetylcholine transmission is especially involved in memory processes, in particular 
short-term memory and attention (88), but cholinergic blockade in the brain has been 
related to a widespread of undesired side-effects such as behavioral disturbances, reduced 
cognitive function, altered emotions, and declined motor function (89-92). 
 
ANTICHOLINERGIC HYPERSENSITIVITY  
Normal aging is accompanied by an increased pharmacodynamic sensitivity to blockade of 
muscarinic receptors in the central nerve system (CNS). Different changes in the cholinergic 
nerve system lead to decreased cholinergic reserves in the aging brain. A structural change 
in the muscarinic binding sites that led to lower binding affinity to acetylcholine, has been 
identified in rat models (93). Furthermore, a reduction in the activity of the presynaptic 
enzyme choline acetyltranseferase reduces the amount of acetylcholine in the CNS followed 
by a significant down-regulation of the number of muscarinic receptors in the brain (40,94). 
Moreover, the age-related pharmacokinetic changes contribute to a further increase in the 
susceptibility to central adverse effects, in particular the increased permeability of the BBB. 
An auxiliary leakage through the BBB is reported in certain conditions that are common in 
the elderly such as neurodegenerative diseases and diabetes (84). Mechanisms involved in 
increased BBB permeability include epithelial shrinkage, opening of tight junctions and 
dilation of the blood vessels resulting in increased blood flow and a leakage of larger 
molecules, as shown in a rat model (84). The vulnerability to central muscarinic antagonism 
is further increased in patients with Alzheimer’s disease. These patients have severely 
impaired cholinergic neurotransmission, secondary to the degeneration of neurons, and it 
has been shown that older people with dementia are hypersensitive to central 
anticholinergic side-effects compared with age matched controls (95). 
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ANTICHOLINERGIC BURDEN(AB) 
The term of drug “burden” might evoke linguistic pedantry as physicians prescribe 
medication based on the anticipated benefits rather than the burden, but as many elderly 
people use several anticholinergic drugs concurrently, the cumulative anticholinergic drug 
exposure might be denoted as a burden. There are in vitro methods and several 
anticholinergic scales that attempt to measure drug-induced AB, but the in vitro methods 
are not standardized and there is no consensus on how to define the drug exposure in the 
scales (96-99). Most of the scales rank the anticholinergic activity (AA) of drugs into four 
levels ranging from 0; that is no anticholinergic activity to 3; that is definite anticholinergic 
activity (96,97,99). Only one scale is adjusted for dose, but this drug  burden index (DBI) 
includes both anticholinergic and sedative medications (98). The anticholinergic score of 
drugs  is based on the drugs’ in vitro AA and/or clinician-rated risk of anticholinergic side-
effects. The total AB of a subject is determined by summation of each drugs’ anticholinergic 
score. Hence, AB is an expert-based measure based on the assumption that anticholinergic 
pharmacodynamic activity is additive in a linear pattern.  
 
SERUM ANTICHOLINERGIC ACTIVITY (SAA) 
The potential anticholinergic properties of many drugs are determined by in vitro detection 
of their competitive binding inhibition of a specific radio-labeled ligand,  tritiated 
quinuclidinyl benzilate (3H-QNB), to muscarinic rat forebrain receptors (100). Many drugs not 
generally considered as anticholinergic, are identified with the ability to displace 3H-QNB 
from muscarinic receptors with this assay technique (68). In 2008 Chew et al. assessed the 
dose-AA relationship of 107 medications at typically doses administrated to older adults 
(68). This method might be useful in quantifying and comparing the AA of different drugs. 
For instance, the dose-AA relationship of atypical antipsychotic medications showed that 
clozapine, olanzapine, and quetiapine had an increase in AA within their therapeutic range, 
while aripiprazole, risperidone and ziprasidone did not (101). Clinicians might use these 
results when choosing between equally efficacious medications, but the interpretation into 
risks of anticholinergic side-effects needs to be considered within the overall clinical status 
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of each patient. Prediction of anticholinergic toxicity depends on functional level, disease 
state, individual pharmacokinetic functions, and pharmacodynamic sensitivity.  
 
The bioassay was originally developed to quantify the total AA in the serum of individuals 
caused by medications and/or endogenous anticholinergic substances. High SAA is 
previously associated with clinical outcomes such as delirium and impaired cognitive 
functions (102,103). However, SAA only indicates that a patient's serum contains compounds 
that affects binding to one or more of the five muscarinic receptor subtypes, but whether 
elevated SAA is caused by medication or endogenous compounds is unclear (104).  
 
ANTICHOLINERGIC DRUG SCALE (ADS) SCORE 
The anticholinergic drug rating scale (ADS) was the first anticholinergic assessment tool 
developed to quantify anticholinergic burden. The ADS score model is developed from a 3-
level anticholinergic classification system of 62 medications that was  published in 1978 
(105). In 2001, Han et al. rated the AA of 340 medication into 0 (none) to 3 (high), based on 
the list from 1978, their clinical experiences, and the available ratings of the drugs’ in-vitro 
AA  (106). In 2006, Carnahan et al. validated and renamed this clinician-rated anticholinergic 
scale to anticholinergic drug scale (ADS) (96). The validation analyses (n = 201) showed that 
ADS was significantly associated with SAA (linear regression), although ADS only explained 
9.5 % of the variation in SAA (96). The amount of variance explained by ADS did not improve 
with a dose-adjusted ADS score model. Moreover, the 1:2:3 weighting strategy appeared to 
be reasonable although 1:2:5 weighting was thought  to be a more precise three-point ratio 
of the relative AA of different drugs (96). Anyhow, the simple 4-point model of 
anticholinergic ratings makes it user friendly in clinical practice. High ADS scores is associated 
with clinical outcomes such as poor memory and executive function (81,90). However, the 
ability of ADS to guide drug interventions and improve outcomes related to AA needs to be 
further studied.    
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OBSERVATIONAL STUDIES OF ANTICHOLINERGIC BURDEN 
Previous cross-sectional studies have related anticholinergic drug use in elderly to increased 
risk of delirium, cognitive impairments, neuropsychiatric symptoms, and reduced physical 
function (107-110). Furthermore, in longitudinal studies, cumulative anticholinergic drug 
exposure is related to deficits in cognitive functioning, but not to elevated risk of dementia, 
and the relation to mortality is uncertain (72,90,111,112). In contrast, one longitudinal study 
did not find any long-term cognitive impact of chronic anticholinergic drug use (113), but the 
overall conclusion is that anticholinergic drugs should be avoided in elderly patients due to 
their high risk of central adverse effects. This conclusion is mainly based on the comparison 
between users and non-users of definite anticholinergic drugs. Still, the presumed additive 
AA of different drugs that have given rise to the assessment of an overall AB is not 
thoroughly validated. AB express the overall risk of anticholinergic toxicity caused by 
multiple drugs. Some of these drugs might interact with each other, some drugs have 
markedly anticholinergic side-effects, while other drugs have potentially AA. Review articles 
have consistently associated high AB with negative cognitive and psychomotor outcomes in 
elderly patients, but there are gaps in the literature (89,114). Randomized prospective 
clinical trials that assess the presumed cognitive improvement of reduced anticholinergic 
burden are lacking and strongly encouraged in various populations (114). Furthermore, there 
are discrepancies in the quantification of anticholinergic burden between the studies and no 
consensus on a complete anticholinergic drug list exists. Table 2 gives an overview of several 
commonly used methods to determine anticholinergic burden in people ≥ 65 years and the 
relation to anticholinergic measures evidenced by observational studies over the last 25 
years. Different methods makes it difficult to compare the studies, but it is also difficult to 
compare the  studies that have used the same method, SAA, because they use different cut-
off values. Table 2 shows  that the relation between the anticholinergic cognitive burden 
(ACB) scale and cognitive measures is weak. Moreover, the finding of a positive relation 
between ACB and mortality have been criticized because the covariates correlated with the 
outcome measure (115). The association between the drug burden index (DBI) and physical 
function is evidenced in different elderly populations and in the one study that disentangled 
between anticholinergic DBI and sedative DBI, the anticholinergic DBI had a stronger 
negative association with physical function than sedative DBI (92). ADS is the only scale that 
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have been significantly related to SAA and high ADS score has also been associated with 
reduced cognitive and executive functions, and the presence of behavioral and psychiatric 
symptoms.   
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Table 2: Association between methods used to determine anticholinergic burden (AB) in the elderly and clinical 
outcomes. Findings from observational studies over the last 25 years. 
Method Estimation 
 of AB  
Study population 
 
Clinical Outcomes 
Serum Anticholinergic 
Activity (SAA); 
measures drugs’ 
displacement of 
3HQNB from 
muscarinic receptors 
expressed in atropine 
equivalents (100).   
 
 
An objective 
measure of the  
∑ in vitro AA of 
serum 
compounds   
 
N = 61 > 65 years,  hospitalized 
patients 
 
N=61 > 80 years, hospitalized 
patients with and without 
dementia 
 
N = 67 ≥ 75 years, medically ill 
inpatients 
Delirium 
Confusion Assessment 
Method (CAM)(102)  
 
CAM(116) 
 
 
 
Delirium Symptom 
Interview(117) 
 
+ 
 
 
- 
 
 
 
+ 
 
N = 90 ≥ 65 years, cognitively 
intact, community-dwelling 
Psychomotoric function  
(gait speed,  
simple response time)(118) 
 
+ 
 
N = 201 ≥ 65 years, cognitively 
intact, community-dwelling 
 
N=26, geriatric patients with 
dementia and behavioral 
disturbance. 
 
N=61 > 80 years, hospitalized 
patients with and without 
dementia 
 
N=152 ≥ 65 years, cognitive 
intact, community-dwelling 
Cognitive impairment  
Mini mental state 
examination (MMSE)(103) 
 
MMSE 
Severe Impairment Battery 
(SIB) (119)  
 
Informant Questionnaire on 
Cognitive Decline in the 
Elderly (IQCODE)(116) 
 
Working memory (120) 
 
+ 
 
 
+ 
 
- 
 
 
- 
 
 
- 
 
 
N=22 demented nursing home 
patients  
Self-care capacity  
Psychogeriatric Dependency 
Rating Scale (91) 
 
 
+ 
Anticholinergic drug 
scale (ADS); 4 ranked 
scale of AA of drugs: 
0 = no known AA 
1= potential AA 
according to in vitro 
studies 
2 = AA observed in 
high doses 
3 = marked 
anticholinergic effects 
(96). 
 
 
Expert-based  
∑ AA of drugs 
based on drug 
characteristics, 
clinical 
experience and 
SAA. 
 
N = 278 ≥ 65 years, medical 
inpatients with and without 
dementia 
 
N = 364 >65 years, hip fracture 
inpatients  
Delirium  
Evaluation of the severity of 
delirium symptoms based 
on CAM (106) 
 
CAM (121) 
 
 
+ 
 
 
- 
 
N= 297 elderly in long-term care  
SAA 
Significant correlation (96) 
 
+ 
 
N = 544 men ≥65, community-
dwelling*  
Cognitive function  
Verbal recall test(90) 
 
 
+ 
 N =461 elderly patients in 
palliative care 
Quality of life 
McGill life  quality scale(81) 
 
+ 
 
N =461 elderly patients in 
palliative care 
 
N = 544 men ≥65, community-
dwelling* 
Functional status 
Australian Karnofsky 
Performance scale (81) 
 
(ADL)(90) 
 
+ 
 
 
+ 
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Anticholinergic 
cognitive burden 
(ACB); 4 ranked scale 
of drugs’ AA  
0 = no AA 
1 = possible in vitro AA  
2 = definite 
anticholinergic 
evidenced by 
association with 
clinically significant 
cognitive 
anticholinergic side-
effects 
3 = drugs with BBB 
permeability and 
association with 
delirium (122) 
 
 
Expert-based  
∑ AA of drugs 
based on drugs’ 
BBB-
permeability, 
risk 
assessments of 
drugs’ cognitive 
side-effects and 
SAA.  
 
N = 147 ≥ 65 years  cognitively 
impaired inpatients 
 
N = 13 004 ≥ 65 years, 
community-dwelling with and 
without cognitive impairments 
 
N= 224 elderly patients with 
Alzheimer’s dementia(123) 
Cognitive function 
CAM(124) 
 
 
Only those using definite 
anticholinergic drugs had 
lower MMSE (72) 
 
 
MMSE 
Severity of cognitive decline 
 
- 
 
 
+
/
- 
 
 
- 
- 
 
N = 13004 ≥ 65 years, 
community-dwelling with and 
without cognitive impairments 
Mortality 
After two years 
(Covariate correlated with 
outcome measures)(72) 
 
+ 
 
N = 87 ≥ 65 years nursing home 
patients with dementia 
Quality  of life 
Multiple engagement 
observations(125) 
 
- 
Anticholinergic risk 
scale (ARS); 4 ranked  
scale of drugs’ AA : 
0 = limited or no risk 
1 = moderate risk 
2 = strong risk 
3 = very strong risk 
(97) 
 
Expert-based  
∑ AA  based risk 
assessments of 
drugs’ 
peripheral and 
central adverse 
effects 
 
N = 132 ≥ 65 years in geriatric 
evaluation management and  
N = 117 males ≥ 65 years  in 
primary care clinics  
Central effects 
 (falls, dizziness, 
and confusion )  
Peripheral effects  
(dry mouth, dry eyes, and 
constipation)(97) 
 
+ 
 
 
+ 
N = 1004 elderly in long-term 
care 
Mortality(126) - 
Drug burden index;  
Anticholinergic  and 
sedative effects of 
drugs ranked 0-1 with 
a hyperbolic dose-
response function (98) 
 
Expert-based  
∑ AA based on 
risk for adverse 
drug events. 
 
N= 1705 males  ≥ 70 years, 
community-dwelling with no, 
mild, or severe dementia 
 
N = 3075 ≥ 70 years, well 
functioning community-
dwelling 
 
N = 932 women ≥ 65 
community-dwelling 
Cognitive function  
Addenbrooke’s cognitive 
examination and trail 
making test(127) 
 
Digit Symbol Substitution 
test (98) 
 
 
MMSE(92) 
 
- 
 
 
 
+ 
 
 
 
+ 
 
N = 3075 ≥ 70 years, well 
functioning community-
dwelling 
 
N = 1705 males ≥ 70 years, 
community-dwelling with no, 
mild, or severe dementia 
 
N = 602 ≥ 70 community-
dwelling 
 
N = 932 women ≥ 65 
community-dwelling**  
Physical function  
Health ABC performance 
score (98) 
 
Physical function 
ADL(128) 
 
 
 
Falls(129) 
 
 
Physical function 
ADL (92) 
 
+ 
 
 
+ 
- 
 
 
 
+ 
 
 
+ 
+ 
*ADS adjusted for drug exposure time 
**Anticholinergic drug burden Index 
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THE PRESENT STUDY 
 
OBJECTIVES  
The powerhouse for this thesis was to contribute to improve clinical knowledge about 
appropriate polypharmacy and drug safety in elderly patients with multiple diseases. 
Pharmacotherapy is an important and complex field of geriatric and nursing home medicine, 
and the motivation was also to highlight the need for a multidisciplinary approach to 
optimize drug treatment in elderly patients.   
The overall objective was to achieve better clinical understanding of the inappropriateness 
of anticholinergic drug use in elderly patients. This objective was chosen because high 
anticholinergic drug burden has previously been associated with an elevated risk of adverse 
effects in observational studies, but the association is not evidenced in prospective 
randomized controlled trials (RCTs). Therefore, we conducted an RCT with the intention to 
translate reduced AB into patient-related improvements in outcomes associated with 
anticholinergic side-effects in elderly people. 
The specific aims of the four studies included in this thesis were:  
i) To compare the potential risk of central anticholinergic adverse effects among 
five drugs used to treat urinary incontinence. 
ii) To evaluate the additive properties of the ADS score model by investigating 
whether increasing ADS scores above 3 was associated with a gradually decline in 
cognitive function in aged people using multiple anticholinergic medications.   
iii) To investigate the clinical effects of reduced anticholinergic drug burden after  
multidisciplinary medication reviews in frail older patients with a high risk of 
anticholinergic side-effects. 
iv) To evaluate the contribution of a clinical pharmacist in the multidisciplinary 
geriatric health care team with patient-related outcomes.  
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v) To evaluate whether genotyping can be used as a clinical tool to identify elderly 
patients at high risk of anticholinergic toxicity by relating anticholinergic 
measures to genotype determined activity in relevant hepatic enzymes involved 
in the metabolism of anticholinergic drugs.  
 
DESIGN 
Paper I)  An in vitro study of the anticholinergic activity of five drugs used to 
treat urinary incontinence.  
Papers II) and IV)  Prospective cross-sectional studies of nursing home residents with 
high anticholinergic activity and no severe dementia 
Paper III)  A multicenter, randomized controlled single-blinded trial, with 
repeated measure design, conducted in nursing home residents with 
high ADS scores and no severe dementia. The effect of the 
intervention was measured four and eight weeks following baseline, 
except for mouth dryness that was only re-measured after four weeks. 
 
MATERIALS  
Paper I) Reference compounds of urinary spasmolytic drugs (USDs) were 
prepared in pooled drug-free plasma obtained from healthy individuals 
and analyzed in their steady state concentration ranges.   
Papers II), III) and IV) Nursing home residents in long-term care were recruited from 22 
nursing homes in Oslo and Akershus from September 2008 to August 
2009. 
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METHODS 
 
STUDY PARTICIPANTS AND DATA COLLECTION  
The inclusion criteria in the RCT study entitled “Pharmacist-initiated Reduction of 
Anticholinergic Drug Activity" (the PRADA- study), were being a nursing home resident in 
long-term care and having a total ADS score t 3. Prior to inclusion, a local caregiver 
evaluated the patients' physical and mental eligibility to conduct the tests included in the 
protocol. Patients considered to have a shorter life expectancy than two month, and 
patients with blindness, deafness, aphasia, delirium, or severe dementia were excluded. 
 
ADS SCORE 
A trained research nurse or the principal investigator determined the ADS sum scores from 
the patients’ drug schedules. In the original ADS, 537 drugs were classified into level 0, 1, 2 
or 3 according to their in vitro AA and clinician-rated AA (96). We modified the AA ranking of 
some drugs in the original ADS according to a more recent comprehensive in vitro study of 
the AA of 107 drugs at therapeutic doses (10). This study detected AA of some drugs not 
present in the original ADS and these drugs were added to the modified ADS (68). We 
considered drugs with less AA than 0.5 pmol/mL atropine equivalents as level 0-drugs. In 
addition we added five new drugs to the modified ADS as we considered these drugs to have  
AA according to the previously published ratings of similar drugs and the specific drug 
characteristics. Table 3, shows the ADS score of drugs with AA used by the study 
participants.  
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Table 3:  ADS score of anticholinergic drugs used by the study participants (n = 87) 
ADS = 3 ADS = 2 ADS = 1 
DRUG ATC code n DRUG ATC code n DRUG ATC code n 
Hydroxycine N05BB01 13 Olanzapine N05AH01 5 Furosemide C013CA01 27 
Clorprotixen N05AF03 12 Nortriptyline N06AA10 3 Prednisolon H02AB06 14 
Alimemazine R06AD01 12 Paroxetine N06AB05 1 Ecitalopram N06AB10 14 
Tolterodine G04BD07 8 Oxacarbacepine N03AF02 1 Digitoxin C01AA05 13 
Amitriptyline N06AA09 5 
   
Ipatropium- 
bromide R03BB01 12 
Dexchlor- 
pheninamine 
R06AB02 5    
Citalopram N06AB04 9 
Solifenacine G04BD08 4    Mirtazapine N06AX11 9 
Levome- 
promazine 
N05AA02 3    
Fentanyl N02AB03 8 
Trimipramine N06AA06 2    Oxycodone N02AA05 6 
Promethazine R06AD02 1    Quetiapine N05AH04 3 
      Diazepam N05BA01 3 
      Ranitidine A02BA02 2 
      Captopril C09AA01 2 
      Clonazepam N03AE01 2 
      Theophylline R03DA04 2 
      Clindamycine J01FF01 1 
      Zuclopenthixol N05AF05 1 
      Fluoxetine N06AB03 1 
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CLINICAL DEMENTIA RATING (CDR) SCALE 
A local caregiver determined the patients’ cognitive function using the clinical dementia 
rating (CDR) scale.  The CDR scale is a global assessment tool that ranks six domains of 
cognitive and functional performances into four categories: 0 = no cognitive impairments, 1 
= mild dementia, 2 = moderate dementia and 3 = severe dementia. The six domains are: 
memory, orientation, judgement and problem solving, community affairs, home and 
hobbies, and personal care. An overall CDR score is calculated by using an algorithm giving 
precedence to the memory domain (130). The CDR is an effective and reliable informant-
based inventory that is validated for use in Norwegian nursing home residents and in 
multicenter studies (131,132). Patients with CDR > 2 were excluded from the PRADA study as 
they were considered to be incapable of executing the test battery.  
 
CHARACTERISTICS OF THE PARTICIPANTS 
We recorded sociodemographic characteristics, i.e. age, gender, weight, educational level, 
smoking habits, and wearing of dental prostheses. We also recorded medical information 
about diagnosis, medical complaints and laboratory measures from the patients’ written 
medical journals. The total number of drugs used, and all available information about each 
drug, (doses, administration route, strength and formulation), were recorded from the drug 
regimens. The patients’ morbidity was assessed from the recorded diagnosis and drug 
therapy using Charlson’s Comorbidity Index (CCI). CCI is a estimate of the prognostic 
morbidity based upon the number and severity of comorbid diseases and is a widely used 
morbidity index in longitudinal studies (133,134). Although, it has been shown that CCI might 
not provide optimal risk adjustment for 1-year mortality in geriatric patients, the CCI was the 
most appropriate and sufficient morbidity assessment tool to be used in this study (133). 
Renal function was  measured by glomerular filtration rate (GFR) calculated according to the 
Modification of Diet in Renal Disease (MDRD) study equation (135). Normal renal function is 
defined as GFR > 90 ml/min, while most people above 70 have decreased GFR despite 
normal serum creatinine (136).  
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NEUROPSYCHOLOGICAL INVENTORY NURSING HOME VERSION (NPI-NH)  
Psychiatric symptoms and behavioural disturbance were assessed by the Norwegian version 
of the Neuropsychiatric Inventory Nursing Home Version (NPI-NH). This was originally a 10-
item informant-based scale developed for determination of behavioural and psychological 
symptoms in patients with dementia (137). A nursing home version (NPI-NH) that comprises 
12 items has been developed and the Norwegian version of NPI-NH has shown good 
reliability and validity (138,139). The items included in NPI-NH are delusions, hallucinations, 
agitation/aggression, depression, anxiety, euphoria, apathy, disinhibition, irritability, 
abnormal motor behaviour, night-time behaviour and eating behaviour, and the 
questionnaire rates frequency (four categories), and intensity (three categories) of each 
item. Frequency is multiplied with intensity (F x I) to generate a item score ranging from 0 to 
12 and adding the item scores gives a sum NPI-NH score between 0 and 144.  In addition, a 
care-giver rates his/her own distress related to each item in a five-point scale from 0-no 
distress to 5-very distressful. According to previous literature we defined symptoms with (F x 
I) ≥ 4 as clinically significant (56). The NPI-NH was included in the protocol as an outcome 
measure, but as the questionnaire is based on information from the nursing home staff, and 
the inter-rater reliability was poor, we decided to use some of the information from the 
baseline NPI-NH solely as descriptive information about patients. 
 
RANDOMIZATION AND BASELINE DATA 
Among the 230 nursing home residents with ASD ≥ 3, 101 were enrolled in the PRADA-study 
and randomly allocated 1:1 to intervention group and control group. The randomization was 
done by a research assistant with no other affiliation to the study. The randomization was 
stratified for 21 nursing homes, as there were no residents recruited from one of the nursing 
homes. The size of the strata varied from 2 to 15, with a median of 4 residents. Of the 101 
residents allocated for the PRADA-study, 87 conducted the baseline assessment. All the 87 
participants were assigned for pharmacogenetic analyses, but 5 were missed due to 
difficulties in blood sampling. Blood and data from the baseline assessment were withdrawn 
for the cross-sectional analyses presented in paper II) and IV).  
44 
 
INTERVENTION-DRUG REVIEWS  
The intervention in the PRADA-study was based on a multidisciplinary drug review within 3 
days after the baseline assessment. Prior to the multidisciplinary drug reviews that took 
place at each nursing home, a clinical pharmacist (the principal investigator), evaluated all 
the participants’ drug regimens guided by the intention to reduce the patients’ overall ADS 
score. In the multidisciplinary drug reviews, possible drug changes were discussed between 
the respective nursing home physician, a nurse with good knowledge of the patients, and 
the clinical pharmacist. Agreements were made whether to discontinue or replace 
anticholinergic drugs with drug alternatives with less or no anticholinergic activity. Drug 
withdrawals were performed stepwise to avoid anticholinergic rebound syndrome. When 
drug alternatives were unavailable, reduction in dosage was attempted in order to reduce 
the anticholinergic burden, but dose reductions did not affect the patients' overall ADS 
score. The drug treatments of all participants were discussed in similar drug reviews, but 
drug changes were only carried out immediately in the patients allocated to the intervention 
group. In the control group the drug changes were conducted by the nursing home physician 
after the last follow up. 
 
ASSESSMENT TOOLS  
The research nurse who worked in this project performed all the clinical assessments of all 
the participants. The whole test battery at each assessment took about one hour to 
administer. 
 
COGNITIVE TESTS 
RECALL OF WORDS  
Three subtests from the neuropsychological test battery developed for the American 
consortium to establish a registry for Alzheimer’s disease (CERAD) were used in this study. 
CERAD’s neuropsychological inventory was established to discriminate between normal age-
related alterations in memory skills and abnormal memory decline that occurs in mild 
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Alzheimer’s disease (AD) (140). The neuropsychological assessment has later been used to 
identify episodic memory deficit associated with mild cognitive impairments (MCI) (141,142). 
The assessment includes neuropsychological measurements of acquisition and learning skills 
which are often the first domains to be impaired in very early AD and MCI. The subtests 
included are verbal fluency, naming, MMSE, 4 wordlist learning tests, 3 constructional praxis 
and recall tests, and one clock drawing test.  CERAD’s neuropsychological test battery has 
been found to have high re-test reliability, inter-rater agreement and longitudinal validity 
(140,142). Based on several reports of the association between anticholinergic drug use and 
poor performances on verbal memory tests, we included the CERAD’s wordlist tests for 
immediate recall, delayed recall and recognition in the present study. Free recall of words 
relies heavily on semantic organization which is shown to be impeded by anticholinergic 
drugs (143,144). It has also been shown that wordlist learning by free immediate recall is a 
sensitive measure to detect mild scopolamine-induced increments in SAA in elderly 
presurgical patients (145). The Norwegian version of the CERAD wordlist test for immediate 
recall was therefore chosen as primary end-point in the PRADA-study (140,146). Prior to the 
administration of the verbal memory tasks, the study participants were asked to memorize 
the words in the wordlist. The wordlist consisted of ten unrelated nouns, each written on a 
card and shown one by one to the participants who were asked to read them out loud. The 
patients immediately recalled as many words as possible in a free order. The task was 
repeated twice and the cards were reorganized between the repetitions. Maximum score 
from the three wordlist learning trials was 30 words, and people between 65-95 years recall 
in average 19-21 words, while less than 18 words is unusual and less than 16 words is 
considered to be abnormal (140). Another task was performed before the participants were 
scored for the correct words recalled after five minutes. In the delayed recall test, 65% of the 
patients with AD do not to remember any words, while cognitively intact people above 80 
years usually remember more than 4 words (140,141). Finally, the ten nouns were mixed 
with ten new nouns and the patients were asked to recognize the words previously read. 
Normally people aged 65-90 years recognize 9-10 words and we therefore decided that the 
recognition task should be the last test in the test battery hoping for the participants to have 
a good feeling of coping after each assessment.  
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THE MINI MENTAL STATE EXAMINATION (MMSE) 
Mini Mental Sate Examination (MMSE), revised for use in Norwegian nursing homes, was 
included in the test battery as a measure of the overall cognitive function of the participants 
(147). The MMSE is a 30-point questionnaire test that includes 20 items within the cognitive 
functions orientation, memory, abstraction, language use and visuospatial ability (148). A 
total score above 27 is considered as normal, while people scoring 25-27 points require 
additional assessments, and below 24 points indicate cognitive impairments. The degree of 
dementia based on the MMSE sum score is given as: 21-24 points defines mild dementia, 10-
20 points defines moderate dementia and below 10 points defines severe dementia (148). 
The MMSE is the most widely used screening tool for global cognitive function, but MMSE is 
an inadequate screening test for specific alterations in memory skills (142). We recorded the 
participants’ general impressions of their own memory skills and their attention towards the 
MMSE during the test situation.  
 
PERIPHERAL ANTICHOLINERGIC MEASURES  
Measures of peripheral anticholinergic activity were included in the test battery to 
investigate the relation between ADS score, SAA and symptoms of adverse drug effects not 
affected by the drugs’ distribution to the brain.  
 
MOUTH DRYNESS 
Saliva flow and secretion are primarily stimulated via muscarinic receptors and mouth 
dryness is a multi-glandular condition. Hence, whole mouth resting saliva flow is a relevant 
measure of drug-induced mouth dryness (149). The saliva flow was only re-measured at four 
weeks follow-up because the peripheral antimuscarinic response in saliva flow was thought 
to be completed within four weeks after the drug changes. We chose a swab technique to 
measure whole mouth resting saliva flow because of its simplicity and feasibility in patients 
with dementia. The method is validated and commonly used, although intra-individual 
variability due to oral anatomical differences have been reported with this method (150). 
We first placed two pre-weighted dental cotton rolls in the patients` mandibula for three 
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minutes and then in the upper vestibules at the opening of the parotid gland ducts for three 
minutes. The cotton rolls were placed in locked tubes after the saliva collection and before 
weighed. The weight difference of the cotton rolls was used to determine the salivary flow 
rate (g/min). Typically, mean resting whole-saliva flow rate in adults is 0.3 mL/min (1 mL is 
equal to 1 gram), but the flow rate is affected by age, gender, and time of measurements 
(149,151,152). In the present study we recorded the time of the measurement, time since 
food, drink, and medicine intake, smoking habits, and dental prosthesis as possible 
confounders of the salivary flow. We strived to measure unstimulated salivary flow rate at 
approximately the same time of the day at each assessment.  
 
RADIO RECEPTOR ANTICHOLINERGIC ACTIVITY BIOASSAY 
The bioassay was first described in 1980 and has been used in research to quantify AA of 
single compounds and peoples’ overall anticholinergic burden for more than 30 years 
(68,100). We used the bioassay for both purposes: paper I describes the quantification of AA 
of five different USDs dissolved in drug-free plasma in their estimated therapeutic 
concentration ranges, while papers II, III and IV include the quantification of the AA present 
in the serum samples withdrawn from the patients participating in the PRADA-study. The 
therapeutic concentration ranges of the USDs were based on references in the literature and 
reported pharmacokinetic data. Blood sampled for measurement of SAA were drawn on 
containers without anticoagulants and kept 1-2 hours in room temperature to facilitate 
coagulation before the serum was isolated by centrifugation (1500 G for 10 minutes). The 
serum was dispensed in two Nunc tubes and frozen at -70 degrees before measurement of 
serum AA. By a mistake, blood samples for measurement of SAA were put directly on ice 
from some of the initially included patients, prohibiting isolation of the plasma matrix. 
During the proceeding patient inclusion, we therefore sampled both full blood and plasma to 
see if radioactive measurements of bound/undisplaced radioligand correlated in paired 
samples of the respective matrixes. A linear correlation analysis showed that AA in paired 
full blood and serum samples was significantly associated P<0.0001. Thus, the full blood 
radioactive values (CCPM) from the initial patients were transformed to ‘plasma values’ by 
application of the formula describing the significant linear correlation between radioactive 
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measurements in full blood and plasma [CCPMplasma = (CCPMblood  0.9543) + 50.96]. The 
assay technique measures the AA of compounds by the degree of displacement of 3H-QNB 
from the muscarinic receptors isolated from rodent brain. We conducted and validated the 
bioassay at an academic research laboratory at The School of Pharmacy based on previous 
literature (68,100). To enable more effective analyses, we modified the original bioassay by 
using 96-well plates instead of single containers and reduced the incubation volume to 240 
μL compared to 2 mL in the original method. The bioassay was performed directly on the 
plates by mixing the samples in the wells, incubate for 1 hour in room temperature before 
separating the 3H-QNB-muscarin complex from unbound 3H-QNB by vacuum filtration and 
washing. In each well the precipitated 3H-QNB-receptor complex was dissolved in 30 μL 
scintillation fluid, gently shook for 30 minutes and the undisplaced radioligand was counted 
using a MicroBeta Plus liquid scintillator detector. High AA of serum compounds is 
proportional with a high degree of displacement and low radioactive counts per minute 
(CCPM). All measurements were performed in duplicates on the same day and in addition 
the USDs were analyzed on three separate days (6 parallels). The mean AA was calculated 
and used in further statistical analyses. For each plate, a standard curve with atropine was 
used as the reference for AA. Prior to determination of the atropine concentrations to be 
used in the standard curve, concentrations of atropine ranging from 0.001nM to 1000nM 
were analyzed to detect which concentrations that captured maximum and minimum 
displacement from the ligand in a one-site competitive binding model. The standard curves 
were fitted to a one-site competitive binding model using GraphPad Prism version 5.01 
(GraphPad Software Inc, CA), and the concentration interval for atropine was set to 0.05-100 
nM. Ten concentrations within 0.05-100nM, were analyzed in four parallels on five separate 
days (20 parallels). In the validation procedure the regression coefficient (R2) and the 
variation coefficient of the estimated values of inhibitory concentration 50% (IC50), 
maximum binding (Bmax) and minimum binding (Bmin) were calculated. The Bmax is the binding 
of 3H-QNB to muscarinic receptors when no competitive AA compounds are present. When 
the system is saturated with AA competitors, less than 20% of 3H-QNB is displaced = Bmin, 
and further displacement of 3H-QNB is caused by unspecific binding. The values of Y, Bmax 
and Bmin are measured in radioactive counts per minutes (CCPM), while log IC50 is 
determined from the curve that is fitted by nonlinear regression. The value of X is expressed 
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in pmol/mL atropine equivalents and calculated from log[x] plotted on the x-axis using the 
equation for competitive binding. The equilibrium below describes the competition of 3H-
QNB and AA competitors (C) for receptor (R) binding. 
 
3H-QNB + C + R  (3H-QNB-R)+ (C-R)  
Competitive binding model: 
Y= Bottom + (Top-Bottom)   
 
 
 
SELF-CARE CAPACITY 
A nurse or a nurse assistant in the nursing homes assessed the patients’ self-care capacity 
using Barthel’s Index (BI). BI is a questionnaire including 10 items such as urinary and fecal 
continence, ingestion of food, mobility, and personal care and each item is staged in terms 
of self-care ability; completely self-dependency gives the highest score. BI is a validated and 
widely used inventory to assess basic ADL functions (153). Unfortunately, the questionnaire 
was filled in by different care-givers at each assessment in the PRADA-study and the inter-
rater agreement was poor. We thereby decided not to use BI as a repeated outcome 
measure, but BI was included in the cross-sectional analyzes in paper II.  
 
GENOTYPING 
Participants were genotyped for the polymorphic cytochrome P450 2D6 (CYP2D6) or 
CYP2C19 hepatic enzymes that are involved in the drug-metabolism of many anticholinergic 
drugs (154). The blood sampled for genotyping was drawn on containers with anticoagulant 
(EDTA tubes) and frozen at -20 degrees before mutation analyses. The genotyping was 
performed at Center for Psychopharmacology, Diakonhjemmet Hospital, using validated and 
certified assays developed for routine analysis (155). Genomic DNA was extracted from 
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blood samples using E.Z.N.A Blood DNA Kit (VWR International, Oslo, Norway). The routine 
genotyping procedure included detection of the single nucleotide polymorphisms CYP2D6 
2549A>del (2D6*3), 1846 G>A (2D6*4), 1707T>del (2D6*6) and 100C>T (2D6*10) and 
CYP2C19 430C>T (2C19*2) and 1075A>C (2C19*3) by TaqMan-based real-time polymerase 
chain reaction (PCR) assays, while CYP2D6 gene deletion (2D6*5) and gene multiplication 
was detected by copy number analysis. The TaqMan real-time PCR assay specifically 
amplified genomic CYP2D6 and CYP2C19 by using a specific set of amplification primers and 
probes which effectively prevent amplification of pseudogenes. Absence of the listed 
mutations was interpreted as presence of the wild-type allele *1-allele encoding functional 
enzyme activity (CYP2C19*1 or CYP2D6*1) (154,155). Phenotypes of CYP2D6 and CYP2C19 of 
the study participants were interpreted from genotype analysis. Patients who carried three 
or more functional CYP2D6 alleles (ultrarapid metabolizers), were excluded and the rest of 
the study population were divided into two phenotype subgroups. Homozygous carriers of 
the detected variant alleles encoding deficient CYP2D6 or CYP2C19 enzyme activity were 
classified as poor metabolizers (PMs), while patients with one or two functional genes were 
classified as extensive metabolizers (EMs).  
 
STATISTICAL CONSIDERATIONS 
The data in this study was analyzed with SPSS (Statistical Program for Social Science) version 
16.0-19.0.  
 
INDEPENDENT VARIABLES  
The independent variables were both continuous and categorical. Two-tailed Spearman’s 
rank correlation matrix was inspected to identify the correlation between all the 
independent variables and to identify possible confounders with significance level p ≤ 0.1. 
Distribution of  the independent variables across the study groups were compared by 
Kruskal-Wallis test in paper II, and by t-tests or Mann Whitney test (continuous variables) 
and Fisher’s exact test (categorical variables) in paper III and IV.  
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DEPENDENT VARIABLES  
All the dependent variables were continuous, but the cognitive measures were discrete 
attaining values on at least 10-point scales. The frequency distributions were inspected by 
histograms to screen the data for skewness, kurtosis and outliers. The discrete variables 
appeared to be normally distributed within the study groups and were therefore analyzed as 
continuous variables in linear models. However in paper III, we used Poisson regression in a 
secondary model of the interventional effect as count data.  The two peripheral measures 
salivary flow and SAA, were log 10 transformed to fit the linear models. The assumptions of 
normality and homoscedasticity of the residuals of the outcome measures were tested with 
Q-Q plot and Levene’s test respectively. The reasons for outliers were checked in the raw 
data and solely the incorrectly entered cases were removed, otherwise the outlying cases 
were considered as consequences of natural variance within the study population. The 
influence of the outliers on the linear models was checked by Cook’s distance.  
 
MISSING VALUES 
One of the reasons why very elderly subjects are excluded from clinical trial is the presumed 
high rate of dropouts and poor adherence to the study protocol. To account for the expected 
high rate of missing data, we targeted a sample size of 40% more participants than required 
to reach a statistical power of 95%, n = 60. The reasons for dropping out were recorded and 
did not seem to be related to the intervention as described in paper III. Furthermore, there 
was no association between missing values and group allocation in a regression model and 
the distribution of the missing values were well balanced between the intervention group 
and the control group in the PRADA-study.  We therefore considered the missing data to be 
missing at random and analyzed the interventional effect primary without imputing data. 
However, in the secondary analyses we imputed the missing data by last observation carried 
forward which is a conservative approach, increasing the risk for type II errors. 
In addition to the drop outs, some of the participants got tired during the assessment and 
lost motivation to complete the test battery. This is reflected by the fact that the final test 
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(the recognition test), had most missing values. In addition there was a low adherence to the 
salivary flow rate test, presumably because this test could be unpleasant for some of the 
participants, especially those with most complaints of mouth dryness. This might have 
caused a selection bias of the observational effect in paper II, probably underestimating the 
relation between ADS score and salivary flow.  
 
EFFECT SIZE IN THE PRADA STUDY 
The required effect size of 30 % improvement in immediate recall was based on efficacy 
studies of cholinesterase inhibitors. We justified that a clinical meaningful cognitive 
improvement of reduced anticholinergic load should be similar to the previously required 
effect size of cholinesterase inhibitors (156). The required cognitive change is also in 
accordance with a recently published study of discontinuation of drugs in nursing homes 
(63). In the a prior power analyses we assumed that the mean score in CERADs immediate 
recall at baseline would be 15-17 ± 5 words. This assumption was based on a previous 
Finnish study and knowledge about the high prevalence of MCI and dementia in Norwegian 
nursing homes, (approximately 80 %) (57,141). However, the observed mean score in our 
study population was less than expected (mean recall of words was 11-12), and hence it 
might have been too optimistic to require a 5 words (30%) improvement of the memory 
performance in patients with probably more severe brain pathology. Although our definition 
of clinically meaningful difference in the CERAD test might have been to strict, it is 
interesting to notice that large observational studies have reported e.g. a 0.32 point decline 
in an immediate recall test of maximum 36 words as statistically significant (90). It is relevant 
to question whether a difference of this magnitude is clinically important in nursing home 
patients with a high prevalence of dementia.  
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RANDOMIZATION 
The intervention was dependent on the collaboration within the multidisciplinary team and 
the local pharmacotherapeutic interest and culture at each nursing home. To stratify for this 
impact, we block-randomized the patients by nursing homes, each nursing home 
representing one stratum. It might be argued that cluster randomization would have been 
more appropriate to avoid leaking from the interventional group to the control group. 
However, this would have required a much larger sample size. The possible leaking of the 
intervention to the control patients is further discussed in paper III.  
 
TYPE I ERROR  
Some people might argue that the level of the statistical analyses should have been adjusted 
for multiplicity to avoid type I errors. However, we decided that since the p-values was far 
from 5% and no significant difference was demonstrated in the PRADA study, adjusting for 
the risk of type I error was superfluous. Furthermore, when our study groups were rather 
equally sized, the F-statistics in the linear models used, is relatively robust in terms of 
violations of normality and homogeneity of variance. 
 
TYPE II ERROR 
The main concern about the choice of statistical models used in this research is the risk for 
type II error. To be sure not to mask a possible effect we have checked all the assumptions 
for linear models in paper II and paper III. Additionally, we have performed secondary non-
parametric analyses of the data.  The risk for type II error is reflected in more details in the 
discussion chapter. 
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ETHICAL CONSIDERATIONS 
Information about the study was given in meetings with the affiliated nursing home staff and 
the participation of each nursing home was contracted. Prior to enrollment, we met all the 
participants assessed as eligible for inclusion, and informed them orally about the study. 
Before randomization, written informed consent was obtained from the all the participants. 
For patients with reduced capacity to assent, their closest relative provided assumed written 
consent. Because people with Alzheimer’s disease have increased sensitivity for 
anticholinergic drugs, it was important to include these patients, despite their lack of ability 
to consent. All the medical records that were used in this project were anonymized. 
We strived to choose methods regarded as feasible and time effective to minimize the test 
burden in this frail study population. This is reflected by our decision to measure mouth 
dryness solely four weeks following intervention. In light of this approach, it might as well be 
argued that one follow up, eight weeks after baseline, would have been sufficient to 
measure the interventional effect.   The control group was offered the same drug review as 
the interventional group, but no changes in prescription were effectuated before after the 
last follow up. However, if serious DRPs had been identified during the reviews, these would 
have been solved immediately. The objective of the intervention was to reach agreement 
with the patients about the drug withdrawal and in those cases where the patients 
disagreed to discontinue the anticholinergic medication, this was respected. Finally, those 
patients with mutations in the hepatic enzymes involved in drug metabolism were informed 
of their genotype. 
The results from our study could easily be transformed to clinical practice and thereby 
benefit the patients in terms of better understanding of appropriate drug prescriptions in 
the elderly.   
The study was approved by the Regional Committee for Medical Research Ethics, the 
Norwegian Directorate of Health and the Data Protection Officer at Oslo University Hospital. 
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RESULTS  
The results of the present study are presented in four papers that are briefly summarized in 
this chapter. The summaries include scientific rationale, main results and conclusion of each 
paper while more details are provided in the original papers, attachment I-IV.   
 
PAPER I 
This study was conducted to assess the relative in-vitro AA for the five urinary spasmolytic 
drugs (USDs) used to treat urinary incontinence. In particular, the AA of the newer USDs 
were of special interest as these drugs are claimed to be more specific to M3 receptors. The 
in-vitro AA reflects the pharmacodynamic potency to induce cognitive side-effects and the 
relative in-vitro AA may assist appropriate selection among commonly used USDs in order to 
reduce the risk of central anticholinergic side-effects. However, the risk of central 
anticholinergic side-effects is also determined by pharmacokinetic factors; in particular the 
degree of brain distribution and the most appropriate USD would be that with the lowest AA 
and the lowest brain distribution. The secondary purpose of this paper was to publish the 
modified radio receptor bioassay (RRA) developed and validated as part of this research 
project.  The rationale for modifying the RRA was to enable more effective analyses of AA 
which might enhance the utility of the bioassay.   
 
In summary this in vitro evaluation suggests that fesoterodine and tolterodine have the 
highest pharmacodynamic potential of central anticholinergic side-effects while darifenacin 
displayed the lowest AA. Moreover, darifenacin is ranked with the lowest brain 
anticholinergic activity. In conclusion darifenacin probably display the lowest risk of inducing 
central anticholinergic side-effects of the five USDs evaluated in this study.  
 
PAPER II 
This prospective cross-sectional study describes the prevalence of multiple anticholinergic 
drug use in 87 Norwegian nursing home residents with and without dementia. The paper 
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explores a gap in the literature regarding anticholinergic polypharmacy and the proposed 
additive properties of the ADS score model in relation to cognitive impairments, activity of 
daily living and peripheral anticholinergic side-effects. The ability of the ADS score model to 
predict central anticholinergic side-effects was evaluated by investigating whether the 
cognitive function gradually declined when the ADS scores increased above 3 in a frail 
elderly study cohort. 
 
The study showed that about one fifth of the nursing home residents had an ADS score of 3 
or higher and about 10 % used at least two anticholinergic drugs concurrently. Nursing home 
residents with dementia had significantly lower ADS scores than those without dementia. 
After adjustment for clinical dementia rate, there was no evidence of a progressive decline in 
cognitive function or ADL when ADS scores increased above 3 (p> 0.10), but in vivo (mouth 
dryness) and in vitro (SAA) measures of peripheral anticholinergic activity were significantly 
higher in patient with ADS score ≥ 6 (p< 0.01). The findings might indicate that the ADS score 
model has limited potential to predict the risk of central anticholinergic side effects in frail 
elderly patients receiving multiple anticholinergic drugs. 
 
PAPER III 
This paper presents the results from the main study entitled Pharmacist-initiated Reduction 
of Anticholinergic Drug Activity (the PRADA-study).  The study is an RCT conducted to supply 
the previous pharmacoepidemiological research with clinical relevancy of high 
anticholinergic drug burden. We aimed to translate reduced ADS score  into improvements 
in relevant geriatric health outcomes in a real-life setting. Secondary, we intended to 
evaluate the contribution of a clinical pharmacist in nursing home treatment care teams with 
patient-related outcomes.  
 
Pharmacist-initiated drug changes significantly reduced the ADS score by 2 units (p< 0.0001) 
in the intervention group, while it remained unchanged in the control group. After eight 
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weeks the adjusted mean difference in immediate recall (primary end-point) was 0.54 words 
between the intervention and control group (95% confidence interval: -0.97, 2.05; p = 0.48). 
The study groups did not differ significantly in any of the other cognitive end-points, saliva 
flow or SAA at either follow-ups (p > 0.19). The significant reduction in ADS score did not 
translate into improved health outcomes which might indicate limited applicability of the 
ADS score to prevent prescription risks in an aged population with high degree of cognitive 
impairments, comorbidities, and polypharmacy. 
 
PAPER IV 
This paper presents the relation between genetic variants of CYP 2D6/2C19 enzymes and  
anticholinergic measures. Genetic heterogeneity in drug clearance has not previously been 
related to AA.  We aimed to investigate whether genotyping might be a clinical tool to 
identify patients at increased risk of anticholinergic toxicity. Based on pharmacogenetic 
analyses of mutations encoding absent CYP2D6 or CYP2C19 metabolism, the study cohort 
was divided into subgroups of poor (n=8) and extensive (n=72) metabolizers and 
anticholinergic measures between the two subgroups were compared.  
 
 Poor metabolizers (PMs) had significantly higher SAA than extensive metabolizers (EMs) (p= 
0.012) and the difference persisted after adjusting for ADS. No significant differences in 
mouth dryness and cognitive function were observed between the subgroups (p>0.3). These 
preliminary findings suggest that older individuals being PMs via CYP2D6 or CYP2C19 are at 
increased risk of higher serum anticholinergic activity than EMs. Whether PMs are also more 
prone to experience anticholinergic side effects needs to be further studied in larger patient 
samples. 
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ADDITIONAL RESULTS 
 
CHARACTERISTICS OF THE STUDY COHORT 
In paper II, the study population was divided into four subgroups based on ADS-scores, in 
paper III, and IV, the study population was divided into two subgroups based on 
randomization and genotyping respectively. Table 4 was included in this chapter to give an 
overview of the baseline characteristics of the whole study cohort. The study population was 
represented by 69 women and 18 men, all above 73 years old and less than 10 % had higher 
education. The study cohort was characterized by high comorbidity score, slightly reduced 
renal function (the reduction in GFR was related to increasing age), reduced salivary flow, 
and substantial polypharmacy (58,136,151,157). Almost 70 % of the study population had 
mild-moderate dementia and two patients had MMSE sum score below 10 indicating severe 
dementia (148). Psychiatric symptoms and behavioral disturbances were highly prevalent in 
the study cohort with almost 80% of the patients having at least one symptom and above 
40% had 1-5 clinically significant symptoms (F x I ≥ 4) (138). Night-time behavior was 
described in 11 patients being the most frequent clinically significant symptom while 
depression, anxiety and irritability was the three most common psychiatric symptoms. The 
patients’  self-care capacity ranged from minimum to maximum points when assessed by 
Barthel’s Index (BI), and approximately 20% was dependent of considerable help in daily 
activities having a BI ≤ 20 (153).  
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Table 4     Characteristics of the study population at baseline (n= 87)  
Characteristics N Median (IQR) and range 
Age 87 85 (82-90), 73-99 
Female gender, n (%) 87 69 (79%) 
Education ≤ 12 years, n (%) 82 75 (91%) 
Daily smoking, n (%) 72 13 (16%) 
Dental prostheses 72  
0 prostheses, n (%)  38 (53%) 
1 prostheses, n (%)  16 (22%) 
2 prostheses, n (%)  18 (25%) 
CDR 87  
0 = no dementia, n (%)  27 (31%) 
1 = mild dementia, n (%)  36 (41%) 
2 = moderate dementia, n(%)  24 (28%) 
Scheduled drugs 87 9 (7-12), 1-18 
Estimated glomerular filtration rate (mL/min) 80 70 (48.3-85.8), 18-207 
Comorbidity score Charlson’s Index 87 4 (3-5), 1-9 
Anticholinergic Drug Score (ADS) 87 4 (3-5), 3-10 
Serum Anticholinergic Activity (SAA) 
(pmol/mL Atropine equivalents) 
81 4.53 (2.45-8.51), 0.18-53.4 
Mini Mental State Examination score (MMSE) 81 20 (16-30), 8-30 
Verbal immediate recall (CERAD) 86 12 (8-15), 0-23 
Verbal delayed recall (CERAD) 85 2 (0-4.5), 0-10 
Verbal recognition (CERAD) 69 6 (4-8), 0-10 
Neuropsychiatric symptoms  (NPI-NH) 83 69 (79%)  
(FXI)  ≥ 4, n (%)  36 (43%) 
Whole mouth resting salivary flow (g/min) 69 0.22 (0.12-0.43), 0.03-1.18 
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GENDER DIFFERENCES 
There were some differences between women and men in the study population. The women 
were older (median age = 87) than the men (median age = 81) and the men produced 
significantly more resting saliva than women (p< 0.010). Interestingly the men’s impression 
of their own memory was better than the women’s, despite no correlation between gender 
and the performance on any of the memory tasks, and the median score on MMS was 
actually the same across the gender.  
 
DIFFERENCES BETWEEN CDR SUBGROUPS 
The study population was divided into three subgroups based on their clinical dementia 
ratings (CDR). The baseline characteristics of the subgroups were compared with Kruskal-
Wallis test for the continuous variables and Fisher’s exact test for categorical variables.  
Table 5 summarize the median (IQR) of the observed values and the difference between the 
subgroups. The performance of the cognitive test decreased significantly with increasing 
CDR and all the cognitive tests were significantly correlated. Moreover, the number of 
scheduled drugs and ADS decreased with increasing CDR. As pointed out in paper II, no 
residents with moderate dementia had an ADS score above 5.  
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Table 5:   Baseline characteristics of the study participants with different dementia ratings 
 
Clinical characteristics 
CDR p-value  
difference 
between 
subgroups 
0 1 2 
Age 84 (81-90) 86.5 (82-91.5) 86 (82-89) 0.54 
Female gender (n) 23 30 16 0.20 
Scheduled drugs 11 (8-14) 9 (7-11) 8 (5-9) 0.01* 
Weight (kg) 61 (51-91) 58.5 (51-73) 65 (54-76) 0.63 
Estimated glomerular 
filtration rate 
(mL/min) 
73.5 (47-94) 61 (42.5-82.5) 70 (59-84) 0.22 
Charlson’s comobidity 3 (3-49) 4 (83-59) 3 (2-5) 0.08 
Whole mouth resting 
salivary flow (g/min) 
.17 (.06-0.33) 0.32 (0.13-0.6) 0.21 (0.17-0.4) 0.19 
MMSE 23 (19.5-26.5) 20 (16-23) 17 (14.5-20) 0.00* 
CERAD Immediate 
recall 
15 (11-19) 12 (9-14) 8.5 (4.5-12) 0.00* 
CERAD delayed recall 4 (2-6) 2 (0-5) 0 (0-2) 0.00* 
CERAD recognition 7 (5-9) 7 (5-9) 6 (4-6) 0.05* 
NPI sum score  1.5 (0-7) 5 (1-18) 6.5 (2.8-12) 0.07 
ADL-BI 65 (37.5-90) 50 (30-75) 47.5 (28.8-
76.3) 
0.10 
Serum AA (pmol/mL 
atropine equivalents) 
5.9 (3-10.7) 4.5 (2.8-7.4) 3.8 (1.9-6.2) 0.86 
ADS 5 (3-6) 4 (3-5) 4 (3-4) 0.03* 
*Significant difference p≤ 0.05. 
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THE RELATION BETWEEN CHANGE IN ADS SCORE ON THE CERAD TESTS 
The change in ADS score on CERAD gives insightful additional information of the evaluation 
of ADS score and we therefore performed an ANCOVA with change in ADS as fixed variable. 
The change in ADS score, ranging from +2 to -6, did not affect the CERAD tests significantly 
(p > 0.35) Neither the comparison of those having their  ADS score reduced with ≥ 2 with the 
remaining patients showed significant differences in immediate recall eight weeks after the 
intervention. We have included a scatter plot that shows the relationship between ADS 
score and CERAD 10 word test for immediate recall eight weeks after intervention, figure 2. 
The plot might indicate that there is a pivotal point between ADS = 0 and ADS =1 associated 
with improved immediate recall. As discussed in paper III, this interpretation is limited by the 
low number of patients with ADS = 0 in our study.  
 
Figure 2: The relation between ADS score and CERADs immediate recall eight weeks after 
intervention  
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DISCUSSION 
 
THE PRESENT FINDINGS RELATED TO PREVIOUS FINDINGS 
 
Darifenacine had the lowest potential for central anticholinergic side-effects 
among five drugs used to treat urinary incontinence 
Overactive bladder (OAB) frequently causes urinary incontinence in elderly people and will 
become an increasingly prevalent problem as the elderly population share increases. 
Management of the urinary symptoms is important for dignity and life quality, but also to 
reduce the risk of falls and fractures related to urge incontinence (158). Drug-induced 
blocking of M3 receptors in the bladder is an effective symptom reliving pharmacological 
treatment, but the urinary spasmolytic drugs (USDs) display a high risk of cognitive 
impairment due to poor muscarinic receptor-selectivity. The potential to cause cognitive 
impairment depends on the drugs’ activity towards muscarinic brain receptors 
(predominantly M1), and the ability to cross the BBB (158,159). Knowledge of the USDs 
relative muscarinic receptor-selectivity and brain distribution might guide the physicians to 
prescribe the drug with lowest risk of cognitive impairments. In premarketing RCTs, 
darifenacine is found to be an effective, well tolerated M3-selective USD with a low degree 
of brain distribution (160). In our post marketing in-vitro based safety assessment of the five 
USDs marketed in Norway, we confirmed the premarketing findings of darifencine. Our 
results suggested that fesoterodine and tolterodine have the highest pharmacodynamic 
potential of central anticholinergic side-effects which also is in accordance with previous 
literature. Overall we found that the relative risk for central side effects was in line with the 
previous findings and the information given by the manufactures of the USDs (158,161-166).   
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The prevalence of Norwegian nursing home residents with a high anticholinergic 
drug burden was approximately 20%, while 10% used more than one 
anticholinergic drug concurrently. The anticholinergic drug burden decreased 
with increasing severity of dementia.    
We reported that each study participant used on average 9 scheduled drugs daily which is 
slightly higher than recently reported in Norwegian nursing homes (58). The use of 
anticholinergic drugs is known to increase with the number of drugs used, and it is therefore 
likely that our inclusion criteria of ADS ≥ 3, biased the selection of nursing home residents. 
We also reported that 21.5 % of the 1101 nursing home residents screened had an ADS 
score above 2 and that 10 % used multiple anticholinergic drugs concurrently. In general,  
the prevalence of anticholinergic drug use has decreased over the past decades (71), but the 
use of anticholinergics among Norwegian nursing home residents was still relatively high 
compared to recent data from community-dwelling elderly (167). Hence, our data might 
support, as previously reported by others, that institutionalization is a risk factor for 
receiving anticholinergic prescriptions (74,80).  The cross-sectional analyses in paper II 
revealed that the patients with moderate dementia used significantly less anticholinergic 
drugs than those without dementia.  However, the difference in ADS score was no longer 
significant after adjusting for the number of drugs taken. In existing literature it is reported 
that dementia is a significant risk factor for receiving anticholinergic drugs and that 
approximately 30% of those using cholinesterase inhibitors receive an anticholinergic drug 
concurrently (73,75,77). Contrary, our results might indicate that the Norwegian nursing 
home physicians are aware of the anticholinergic hypersensitivity related to the 
pathophysiological process of Alzheimer’s dementia and hence avoid anticholinergic drug 
prescriptions to patients with more severe dementia. However, as the ADS score difference 
not persisted significant after controlling for the number of drugs taken, it is more likely that 
the observed difference reflects that patients with dementia generally receive less drugs 
than cognitively intact patients and are as well at risk of under-prescription because of 
communication problems (74).  
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ADS had limited clinical utility as a prescription tool to assess risks of central 
anticholinergic side-effects 
Based on previous  literature of anticholinergic burden, our clinical findings was contra-
intuitive (114). Our cross-sectional baseline-results did not support a progressive decline in 
cognitive function when the ADS score increased  above 3. Neither did a significant reduction 
in the patients’ ADS sum scores translate into cognitive improvements or reduced peripheral 
anticholinergic activity in our interventional RCT. Our results were consistent and the overall 
conclusion is therefore that we do not support implementation of the ADS score model as a 
prescription tool to reduce the risk of central anticholinergic adverse effects in a frail elderly 
population. However, It is important to notice that our findings do not counteract with 
previous observations of a significant increased risk of cognitive impairments in older adults 
with high AB compared with non-users of anticholinergic drugs (72,103,109,168). 
Accordingly, we might have achieved another result if the ADS score had been reduced to 
zero in the interventional group. It might seem quite obvious that the risk of side-effects is 
significantly increased in users compared to non-users of anticholinergic drugs, but the 
cross-sectional studies have thoroughly increased our knowledge about what harm these 
drugs might cause in elderly people. Longitudinal observational studies have further 
enhanced our knowledge of the cognitive risks associated with cumulative anticholinergic 
drug exposure and  that discontinuation of anticholinergic treatment reversed the elevated 
risk of cognitive decline (90,112,169). The one interventional study conducted prior to the 
PRADA-study, is unfortunately limited by the risk of type I error (67) while another RCT have 
solely investigated the effects of biperiden withdrawal (170). Overall, the risks associated 
with anticholinergic drugs used in the elderly is thoroughly investigated, but as shown in 
table 2, the results from the observational studies of AB is not as conclusive as previously 
reported (114). Even so, our lack of interventional effect was unexpected and should be 
confirmed in larger elderly populations.   
 
The pharmacist-initiated reduction of the patients’ ADS score was significant, but 
the reduction did not translate into improvements in patient-related outcomes. 
The RCT was partly motivated by the intention to show that clinical pharmacists contribute 
to improve health outcomes in geriatric patients with complex drug regimes. We found that 
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the contribution of a clinical pharmacist in the multi-disciplinary drug reviews did result in a 
significant reduction in the ADS score, but this reduction did not translate into 
improvements in patient-related outcomes. Previous trials have shown that the inclusion of 
clinical pharmacists in geriatric evaluation and management units, and in nursing homes, 
improved the appropriate use of medicines and reduced  potentially harmful drug-related 
problems (45,58). However, studies that translate these potentially positive effects into 
patient-related health outcomes are limited and inconclusive (49,50).  We did not succeed in 
our intention, but the drug changes performed in the drug reviews were all guided by the 
ADS score model. Therefore, our intervention should not be considered as a general 
evaluation of complete multi-disciplinary drug reviews. Furthermore, the patient-related 
outcomes were solely related to anticholinergic drug effects. It is important to underline that 
the PRADA-study was not designed to evaluate the effect of pharmaceutical care in nursing 
homes. Pharmaceutical care includes more than one drug review guided by the intention to 
reduce the patients’ ADS scores.  However, despite no effects on the patient-related 
outcomes with our approach, the result reflects the possibilities of reducing a potential risk 
and hence increase drug safety by including a clinical pharmacist in geriatric health care 
teams.  
 
SAA was significantly higher in poor versus extensive CYP P450 2D6/2C19 
metabolizers in an elderly population with high ADS scores. 
To our knowledge the relation between genetic heterogeneity in drug clearance and 
anticholinergic measures has not previously been investigated. We found that high levels of 
serum anticholinergic activity (SAA), was significantly associated with mutations in 
cytochrome P450 2D6 and 2C19. Those with no activity in these drug metabolizing hepatic 
enzymes (PMs) had significantly higher SAA compared to those with enzyme activity (EMs). 
We did not find any significant differences in clinical outcomes between PMs and EMs, but 
the clinical importance of our preliminary findings needs to be further investigated. 
However, other clinical studies have reported that the serum concentration of many 
anticholinergic drugs is substantially increased in CYP2D6 or CYP2C19 PMs versus EMs and it 
is therefore likely that the present elevated SAA is related to reduced anticholinergic drug 
clearance (65,171).     
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METHODOLOGICAL WEAKNESSES 
 
LIMITATIONS OF THE IN-VITRO DETERMINED SAA  
We developed a more effective method for determination of  in vitro AA which was used in 
all the papers included in this thesis, but the bioassay has certain drawbacks. SAA is a 
measure of peripheral circulating anticholinergic compounds, and does not consider the 
concentration of the anticholinergic drugs in the brain. One study has even shown that SAA 
did not correlate with the cerebral cholinergic function as measured by EEG (116). Still SAA 
has been related to several central anticholinergic side-effects (91,102,103). However, the 
prediction of central side-effects need to be adjusted for the degree of brain distribution of 
the drug. In example, we reported that the in vitro AA of oxybutynin was relatively low 
compared to other urinary spasmolytic drugs, but clinical studies have shown that 
oxybutynin can cause cognitive impairments and this might be explained by relatively higher 
brain distribution (172,173). Other limitations of the binding assay is that it does not 
disentangle between antagonistic and agonistic activity towards the muscarinic receptors 
nor the specific binding to each muscarinic subtype. It has also been criticized that the levels 
of SAA vary considerable between different reports (104). This might partly be explained by 
intra-laboratory heterogeneity in the assay methodology. For instance different curve 
models might have been used to calculate the atropine standard curves used as a reference 
for AA (96,174).  Furthermore, the bioassay is not standardized and several different units of 
the AA exist in the literature (104). Finally, the level of SAA is determined by medications, 
drug metabolites, and endogenous anticholinergic substances and there has been shown 
that the level of SAA increased during acute illness, without any relations to drug changes. 
The SAA increment  was reversed following illness recovery and it was suggested that SAA 
might be increased due to a nonspecific stress response to illness in older persons (175,176).  
Accordingly, naturally occurring substances such as cortisol have shown binding affinity to 
muscarinic receptors in vitro (104). Moreover, plasma proteins have inhibited the binding of 
the 3H-QNB in the bioassay and interfered with the resulting SAA levels (177).  
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LIMITATIONS OF ADS 
ADS is an expert-based score model to determine the overall AA of a subject based on the in 
vitro detected AA of different drugs. Hence, the limitations of SAA and ADS are overlapping, 
but ADS has some additional drawbacks related to the 3-propotional categorization and the 
summation of drugs’ AA. Firstly, the ADS is developed to estimate an overall drug response, 
but the dose-response relationship of each drug is not considered in the model.  This means, 
for instance,  that a small dose of digitoxin, furosemide and ecitalopram, all having an ADS 
score of 1, are considered to cause the same anticholinergic burden (ADS sum score = 3), as 
one high dosage of hydroxycine. Secondly, the relative AA of different drugs is probably not 
proportional to a 1:2:3 ratio. Thirdly, the overall anticholinergic drug response is influenced 
by differential aging, drug-drug interactions, and multiple diseases, in particular the stage of 
dementia, but the inter-individual heterogeneity is not considered in the ADS-score model. 
This is a general and important drawback of all inappropriate drug lists used as geriatric 
prescription tools. Finally, there is a lack of consensus on how to define the anticholinergic 
drug exposure in the different methods used to determine anticholinergic burden and a gold 
standard is required to achieve internal as well as external validity (33). In conclusion, all the 
ADS score models simplifies complex pharmacological mechanisms into categories and it is 
reasonable to question whether ADS sum score possible can predict an overall brain effect of 
multiple anticholinergic agents in older people with multiple diseases.  
 
LIMITATIONS OF GENOTYPING 
We suggest that genotyping could be a clinical tool to identify patients at increased risk of 
anticholinergic drug toxicity, but the clinical importance of determining genetic variants 
might be questioned by the effect size of the clinical outcome (178). Furthermore, the 
relationship between genetic variants and anticholinergic drug responses is still unclear. 
However, clinical implication of pharmacogenetic testing is strengthened by the 
unpredictable drug response in the elderly, and in the cases of long-term treatment of 
anticholinergic drugs with a small therapeutic range.   
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We divided the study population into two phenotype subgroups according to CYP2D6 and 
CYP2C19 genotypes. There are limitations in interpreting the genotype-phenotype relation 
into poor and extensive metabolizers based on the most relevant alleles. Despite the 
limitations, the genotype determination of CYP 2D6/2C19 deficiency is consistent and of 
major importance in this relatively small study. We don’t think a more accurate prediction of 
the catalytic activity within the EMs would interfere with our findings.  
 
OTHER LIMITATIONS 
The interpretation of the results in  paper I and IV is limited by the uncertainty of the clinical 
relevance of the in vitro AA. Although high levels of SAA have previously been related to 
cognitive impairment (103), we could not confirm this relationship. Hence, the results in 
paper I must be understood as a relative pharmacodynamic potential of USDs to cause 
central anticholinergic effects.  The results in paper IV was regarded as preliminary and is 
limited by the few PMs.  
 
CONCERNS OF TYPE II ERROR 
We unexpectedly retained the null-hypothesis in this study and this generated a  general 
concern of type II error.  Test sensitivity is an important determinant of the interventional 
effect and we can not rule out that other measures such as executive functions and physical 
performance would have been more sensitive to possible improvements of the drug 
changes.  The time schedule is another determinant of the effect, and longer observation 
time might have been required to regain the dynamics in cholinergic brain transmission after 
drug changes. However, the consistency between our cross-sectional and interventional 
results , and the reliability between the primary and secondary statistical analyses of the 
effects, strengthened our conviction in the null-hypothesis.     
 
INTERNAL VALIDITY 
Internal validity is a general problem with studies conducted in very elderly populations 
because of selection bias. To ensure that our study population consisted of a representative 
sample, our inclusion strategy was broad.  Nevertheless, we experienced a low inclusion 
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rate, which might reflect that very elderly people and their proxies generally are more 
reluctant to participate in research trials (36).  The great heterogeneity of very elderly 
subjects represents a further challenge to the internal validity, but even so, age itself should  
no longer be considered as a reason for exclusion from RCTs (36).  A high drop out rate is 
also a difficulty that needs to be adjusted for because very elderly study participants with 
multiple diseases often have lower adherence to the protocol than younger healthier ones 
(33).  Despite the challenges that our study population represents, the overall impression 
was  that the participants were positive to conduct the tests. We even observed a significant 
within group improvement in cognitive performances in both study groups which might 
reflect their willingness to cope with the cognitive tasks given them.  
 
EXTERNAL VALIDITY 
Achieving external validity is challenging when conducting a study under real-life conditions 
as the characteristics of the study populations might affect the results (33).  Despite lowered 
generalizing strength of the results, it is very important to evaluate drug effects and 
combinations of drugs in the patients that actually use the drugs, under those circumstances 
they use them.  The external validity of our results might be reduced by our modifications of 
the original ADS score. The lack of consensus of how to determine anticholinergic burden 
reduces the external validity of all the studies using anticholinergic assessment tools and it 
makes it difficult to compare the findings between the studies. The external validity of the in 
vitro study might be limited by the distribution of muscarinic receptor subtypes in the 
sonicated rat cerebrum that we used. As biological material always differ, this is a  general 
limitation in all studies of biological nature.   
 
CONSEQUENSES OF THE RESEARCH 
This study underlines the need for more RCTs in real-life settings to validate the clinical 
utility of anticholinergic risk assessment tools. Generally, there is an increasing amount of 
pharmacoepidemiological studies reporting high risk:benefit ratio related to the 
pharmacological treatments of elderly people. The risk:benefit ratio is based on the amount 
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of expert-rated inappropriate medicines used (30,31). These studies are often presented in 
an overwrought press which might generate a general scare and poor adherence to drug 
prescriptions in the elderly. Anticholinergic drugs are defined as inappropriate in older 
people. To be in line with the observational studies we might interpret the lack of 
improvements related to reduced anticholinergic burden, as a consequence of the study 
limitations. On the other hand, the lack of effects might also be interpreted as a 
consequence of the complexity within geriatric clinical pharmacology. We might, in our 
attempt to predict risks by compulsive classification of central drug effects, have 
manufactured an unnecessary worry of cognitive side-effects related to certain drugs. There 
is a need for further investigations, and our results needs to be confirmed in larger samples, 
but anyhow, the practical consequences of our research might be summed up in one 
sentence written by James Malone-Lee in a letter in British Medical Journal in 2011: “Nature 
is inimicial to categories-biological variations is continuously dispersed.”     
 
FUTURE DIRECTIONS 
Postmarketing pharmacoepidemiologic safety studies are important to identify risks of 
adverse drug effects in elderly people (33). However, withdrawal of high-risk medicines has 
to be translated into relevant health improvements before changes in geriatric prescription 
guidelines should be made. Generally, there is a need for more RCTs in different elderly 
populations to confirm or reject the findings from the observational safety studies (33).   
Working with this thesis has inspired to conduct another RCTs with the objective to evaluate 
the possible improvement from discontinuation of drugs with high risk of adverse CNS-
effects in cognitively intact and cognitively impaired elderly patients. Based on recent 
observational studies, the clinical outcomes of such drug changes could be for instant grip 
strength, falls, and ADL in addition to global cognitive status (MMS) (128,179). These are all 
relevant outcomes of drug safety in geriatric patients.   
It is well established that definite anticholinergic drugs (ADS = 3) are inappropriate in elderly 
patients due to their high risk of cognitive side-effects. However, the anticholinergic scales 
categorize many drugs, not normally considered as anticholinergic, as potentially 
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anticholinergic based on their previously shown in vitro AA (ADS =1) (96,122). To our 
knowledge, the anticholinergic potential of the 71 drugs with ADS =1, is not confirmed in 
observational studies. It would have been interesting to further evaluate the in vivo AA and 
possible cognitive impact of these drugs in larger population samples. Maybe the drugs with 
ADS = 1 do not represent any clinically important risk of anticholinergic side-effects? 
Furthermore, it would have been valuable to assess whether our relative in vitro detection 
of potentially brain AA of the five USDs was confirmed in vivo studies. In particular, the 
potentially favorable safety profile of darifenacine need to be investigated in elderly study 
populations.   
Despite that 70 % of the present nursing home population had mild-moderate dementia, 
only four patients were treated with cholinesterase inhibitors. Several 
pharmacoepidemiological studies have reported that 30% of those using cholinesterase 
inhibitors use anticholinergic drugs concurrently (75,76). Some previous preliminary results 
have suggested that chronic concomitant exposure to anticholinergics are associated with 
significant deleterious effects on cholinesterase therapy (180). The clinical importance of this 
drug-drug interaction would have been interesting to study further. There are also diverging 
observational findings of the association between chronic anticholinergic drug exposure and 
the development and progression of dementia, and this should be clarified in further 
longitudinal studies (112,169).  
One study reported that anticholinergic drugs had more severe negative impact on physical 
function than sedative drugs in elderly patients (92). This would be interesting to analyze 
further because there might be an impression of less harm related to anticholinergic 
sedatives compared to traditional hypnotics used to treat sleeping disorders in the elderly.   
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1WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT 
 Drugs with anticholinergic properties are frequently used in older people despite their 
high potential of precipitating central and peripheral adverse effects
 Many institutionalized older persons use several drugs with potential anticholinergic 
effects concurrently
 Observational studies have reported that patients with a high anticholinergic burden,
i.e. a score of 3 or higher on the anticholinergic drug scale (ADS), have increased risk 
of cognitive impairment compared to non-users of anticholinergics (ADS score ‘0’).
WHAT THIS PAPER ADDS
 About one fifth of nursing home residents had an ADS score of 3 or higher 
 Residents with dementia had lower ADS scores than those without dementia. 
 After adjustment for clinical dementia rate, there was no evidence of a progressive 
decline in cognitive function when ADS scores increased above 3 in frail nursing 
home residents.    
2Summary
AIM
This study evaluated a presumed gradual decline in cognitive function in nursing home 
residents when the anticholinergic drug scale (ADS) score increased above 3.
METHODS
The study population was recruited from 21 nursing homes in Norway. Criteria for inclusion 
were ADS score DQGQRVHYHUHGHPHQWLDGHILQHGDV&OLQLFDO'HPHQWLD5DWLQJ&'5
score < 3. Primary cognitive end-points were CERAD 10-word lists for recall and Mini
Mental State Examination (MMSE). Secondary end-points were activity of daily living 
(ADL), mouth dryness and serum anticholinergic activity (SAA). The patients were stratified 
into subgroups according to ADS score, i.e. a reference group with score 3, and test groups 
with scores 4, 5 or . End-points were compared by analyses of covariance (ANCOVA).
RESULTS
Overall, 230 of the 1101 screened nursing home residents (21%) had an ADS score . After 
exclusion 101 residents were recruited and among these, 87 managed to participate in the 
study. No significant differences were detected in cognitive function or ADL when ADS 
increased above 3 (p> 0.10), but in vivo (mouth dryness) and in vitro (SAA) measures of 
peripheral anticholinergic activity were significantly higher in patient with ADS score  (p< 
0.01).
CONCLUSION
The present study does not support a progressive decline in cognitive function with ADS 
score above 3. This might indicate that the ADS score model has limited potential to predict 
the clinical risk of central anticholinergic side effects in frail elderly patients receiving
multiple anticholinergic drugs.
3Introduction
Many commonly prescribed drugs have shown affinity to muscarinic receptors in vitro and 
may cause central and peripheral antimuscarinic symptoms in vivo [1]. Aged people, 
especially those who are cognitively impaired, have increased sensitivity to central 
antimuscarinic adverse effects due to reduction in cholinergic neurotransmission, and use of 
antimuscarinic drugs (in the following referred to as ‘anticholinergic’) has been associated 
with reduced cognitive and physical function in the elderly [2-4]. Still, anticholinergic drugs 
are frequently prescribed to elderly people, and previous studies have shown that nursing 
home patients often use several anticholinergic drugs simultaneously [5;6].
It is believed that drug-induced anticholinergic activity (AA) is additive and that the overall 
anticholinergic burden determines the risk of adverse effects [4;7-9]. In 2006, Carnahan and 
colleagues published the Anticholinergic Drug Scale (ADS) score model for estimation of the 
overall anticholinergic burden. The ADS has four score levels for each included drug, ranging 
from level ‘0’ (‘no known AA’) to level ‘3’ (‘markedly AA’) [8]. Summation of each 
medication’s ADS score reflects the total anticholinergic burden of a subject. 
Large observational studies using the ADS score model have previously reported that high 
anticholinergic burden increases the risk for peripheral and central side effects when 
comparing patients with ADS score ‘0’ (non-users of anticholinergics) with those using 
anticholinergics [4;9-11]. However, the proposed additive properties of the ADS inventory 
have not previously been evaluated. Thus, it is unknown whether cognitive function gradually 
decline in aged people who are exposed to an increasing number of anticholinergic 
medications. The aim of the present study was therefore to investigate the cognitive function 
when the ADS scores increased above 3 in frail nursing home residents.    
4Methods
Study population
The participants were long-term nursing home residents recruited from 21 institutions in two 
different Norwegian counties during 2008-2009. Anonymized medical records were screened 
for anticholinergic drugs by a clinical pharmacist (HK) and a trained study nurse. 
Anticholinergic drug score was assessed using the ADS score model published by Carnahan 
et al. in 2006, with some modifications based on a more recent, comprehensive in vitro 
screening of anticholinergic activities at therapeutic serum concentrations published by Chew 
et al. in 2008 [1;8]. Patients with overall ADS score ZHUHFRQVLGHUHGIRULQFOXVLRQE\D
local caregiver who evaluated their physical and mental eligibility to participate. Patients with 
blindness, deafness, aphasia, delirium, or severe dementia, i.e. score 3 on the Clinical 
Dementia Rating scale (CDR) were excluded [12;13].
Outcome measures
Cognitive function
One study nurse, blinded for the patients’ ADS scores, performed the cognitive tests on all the 
participants. The cognitive test battery included the Norwegian translated version of the 10 
words tests of immediate recall, delayed recall, and recognition, from the Consortium to 
Establish a Registry for Alzheimer Disease (CERAD) neuropsychological test battery [14]
and the Mini Mental State Examiation (MMSE), revised for use in Norwegian nursing homes 
[15]. The CERAD subtests were chosen as they can sensitively differentiate between 
cognitive impairments of different severity [16].
5Self-care capacity
The patients` self-care capacity was assessed using the Barthel`s Index of Activity of Daily 
Living (ADL) [17]. The ADL scores of the patients were determined by a nurse or auxiliary 
nurse at each nursing home included.
Mouth dryness
A swab technique was used to measure the resting whole mouth saliva flow rate. The test was 
performed by first placing two pre-weighted dental cotton rolls in the patients' lower jowl for 
three minutes and then in the upper vestibules at the opening of the parotid gland ducts for 
three minutes. The weight difference of the cotton rolls was used to determine the salivary 
flow. This test has been shown to be reliable and practicable in cognitive impaired elderly 
adults [18].
Serum anticholinergic activity
Blood was sampled from the patients for measurement of serum AA (SAA) using a modified 
version of the radio receptor assay published by Tune and Coyle in 1980 [19]. In the modified 
assay, samples of 20 μl were applied in 96 well plates for high throughput analyses of SAA 
[20]. A standard curve with atropine (0.05 to 100 nM) was used as reference for 
anticholinergic activity. Standard curves were fitted to a one-site competitive binding model 
using GraphPad Prism version 5.01 (GraphPad Software Inc, CA). 
Covariates
Information about age, gender, educational level, smoking habits, time since last meal and 
medication intake, and use of dental prostheses, was collected from the patients’ nursing 
home records. Further, information about other possible confounders, such as diagnoses, 
6neuropsychiatric symptoms, serum creatinine, the use of cholinesterase inhibitors and the total 
number of drugs used was recorded. Co-morbidity was assessed by the Charlson Co-
morbidity Index [21]. The frequency (F) and intensity (I) of neuropsychiatric symptoms were 
rated by use of the Norwegian version of the neuropsychiatric inventory for nursing homes 
(NPI). Each symptom with item score )[,ZDVDVVHVVHGWREHRIFOLQLFDOUHOHYDQFH[22].
Glomerular filtration rate (GFR) was calculated according to the Modification of Diet in 
Renal Disease (MDRD) study equation [23].
Statistical Analyses
Prior to the statistical analyses, the patients were stratified into four subgroups according to 
overall ADS scores; i.e. a reference group with score 3 and three test groups with scores 4, 5, 
and 6-10, respectively. Distribution of the covariates across the four strata was compared by 
Kruskal-Wallis test. All the outcome measures were explored by distribution plots and 
descriptive analyses. Log 10 transformations of SAA and saliva production were conducted to
attain normal distribution. Two-tailed Spearman’s rank correlations between the covariates 
and the outcome measures were inspected to identify possible confounders and collinearity 
between the covariates. Analyses of covariance were performed to compare the mean 
difference in each outcome measures between the test groups (ADS = 4, 5 and and the 
reference group (ADS = 3). We adjusted for the possible effects of the imbalanced covariates 
with significance level  0.1. In addition, analyses of cognitively intact patients and patients 
with mild-moderate dementia were performed separately in each ADS-subgroup. We included 
the 45 patients with severe dementia in a Mann-Whitney test performed to compare the ADS 
scores in patients with dementia (CDR 1, 2 and 3) versus patients without dementia (CDR = 
0). All statistical analyses were performed using PASW Statistics for Windows version 19 
(SPSS Inc., Chicago, USA).
7Ethics
We obtained written informed consent from all participants. For participants with substantial 
cognitive impairment, written informed consent was collected from the closest relative, in 
accordance with Norwegian legal regulation. The study was approved by the Regional 
Committee for Medical Research Ethics, the Norwegian Directorate of Health and the Data 
Protection Officer at Oslo University Hospital.
8RESULTS
Of the 1101 screened residents, 230 (21 %) had an ADS sum score . After exclusion based 
on predefined criteria, 101 nursing home residents were recruited. Among these 87 managed 
to participate and comprised the finally included study population. Figure 1 shows the sample 
selection and the reasons for exclusion. The nursing home staff considered 99 of the patients
with ADS WREHincapable of executing the tests; 45 due to severe dementia (CDR = 3)
and 44 because of physical impairments such as aphasia, loss of hearing or sight. The 87 
patients finally included were allocated to the ADS subgroups (score 3, n=35; score 4, n=22; 
score 5, n=16; and score Q 
Clinical characteristics of the study participants stratified by their ADS score are presented in 
table 1. The study population (n= 87) comprised 69 women and 18 men, all aged above 73 
years, women being older (median age 87 years, interquartile range (IQR) 84-92) than men 
(median age 81 years, IQR 79-85). Their median Charlson co-morbidity score was 4 (IQR 3-
5), almost 70 % of the included patients had mild to moderate dementia (CDR 1-2), and four 
patients were recorded with clinical significant symptoms of depression (NPI item score 
The median number of drugs used on a regular basis was 9 (IQR 7-12), and four patients were 
treated with cholinesterase inhibitors. The distribution of number of scheduled medications 
and degree of dementia (CDR) were significantly different across the categories of ADS 
score, (p = 0.004 and p = 0.007 respectively, in Kruskal-Wallis test). Patients with ADS score 
KDGOHVVGHPHQWLDDQGXVHGPRUHGUXJV on a regular basis than the other groups and none 
of the patients  with moderate dementia (CDR = 2) had an ADS score 7KHGLVWULEXWLRQRI
patient with dementia (CDR = 1, 2 or 3) versus patients without dementia (CDR = 0), was 
significantly asymmetrical across the ADS categories (p = 0.011), and the patients with 
dementia had significantly lower ADS scores than the patients without dementia (p = 0.024).  
9The 31 different anticholinergic drugs used by the participants are listed in table 2. Fifty-nine 
patients used one drug with an ADS score of 3 (hydroxyzine, chlorprothixene, and 
alimemazine most frequent, being used by 15 %), while three patients used two drugs in this 
category. The most frequently used anticholinergic drug regardless of score was furosemide 
(ADS = 1). Psychotropic drugs with anticholinergic properties were common in the nursing 
home patients. Overall, 50 % used an antidepressant and 27 % used an antipsychotic listed in 
the ADS score model. Two patients used five different anticholinergic drugs and five patients 
had a total ADS score . Altogether, the 87 patients used 204 prescribed anticholinergic 
medications on a regular basis. 
The median values of immediate recall, ADL, salivary flow and SAA in each ADS subgroup 
are illustrated in Figure 2. Table 3 shows unadjusted and adjusted mean differences in end-
points between the ADS subgroups with reference to ADS = 3. CDR and number of 
scheduled drugs were significantly imbalanced between the ADS subgroups, but only CDR 
was identified as a covariate with sign level p DQGWKXVDGMXVWHGIRULQWKHPXOWLYDULDWH
model. In the unadjusted and adjusted models, no significant differences in cognitive end-
points were detected between patients with increasing ADS scores (p > 0.11). Separate 
analyses of cognitively intact patients (n = 27) and patients with dementia (n = 60) did not 
show any significant cognitive decline with increasing ADS scores in any of the subgroups (p 
> 0.45 and p > 0.65, respectively).
The self-care capacity increased significantly with increasing ADS scores (p = 0.05), and the 
participants with ADS KDGDSSUR[LPDWHO\EHWWHUVHOI-care capacity than the 
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participants in with ADS = 3, p = 0.014 (table 3). After adjusting for the imbalance in CDR 
the difference in ADL did not persist statistically significant (p = 0.13).
The measure of peripheral circulating anticholinergic activity (SAA), and the peripheral 
clinical measure mouth dryness, were both significantly increased when participants with 
ADS score Zere compared to participants with ADS score = 3 (p < 0.01) (table 3). No
differences in peripheral activity measures were observed between test groups with ADS 
score of 4 or 5 compared to score 3 (p > 0.15). The significant increase in SAA and mouth 
dryness in patients with ADS score SHUVLVWHGDIWHUFRQWUROOLQJIor differences in CDR (p < 
0.02). 
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Discussion
We found that one fifth of nursing home residents had an ADS score while around 10 % 
had ADS scores 4-10. This implies that a substantial proportion of the patients used at least 
two anticholinergic drugs concurrently. Large observational studies have reported that a high 
ADS score is a significant predictor of cognitive impairments, but the ‘dose-response’ 
relationship in ADS KDVQRWSUHYLRXVO\EHHQLQYHVWLJDWHG[2;4;8-11]. As no significant 
differences in cognitive outcomes were observed between the patient subgroups, our results 
do not support a gradual decrease in cognitive function when ADS score increases above 3.
However, the number of nursing homes patients eligible for inclusion was limited, and larger 
studies would be desirable to confirm the present findings. 
The lack of association between ADS score and cognitive function in the current study could 
be explained by several factors:
Firstly, the ADS score model has a rather simple concept which does not take into account
systemic drug exposure, distribution to the brain or pharmacodynamic interactions. The
cognitive decline is dependent of the AA in the brain which is previously reported to be dose-
dependent, especially in people with dementia. [24] Moreover, the pharmacodynamic brain 
effects of multiple anticholinergic drugs are probably not additive in a linear pattern that can 
be predicted by the ADS score model.
Secondly, since aging and Alzheimer Dementia (AD) have previously been associated with 
hypersensitivity to anticholinergic drugs due to loss of cholinergic neurotransmission, it is
possible that a saturation of the receptors might be reached by excessive anticholinergic 
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activity (ADS [25;26] As a consequence, a further anticholinergic increase cannot 
displace more acetylcholine from the muscarinic receptors. 
Finally, the present variability in anticholinergic drug sensitivity related to advanced age, 
multi morbidity, different degree of dementia and the multiple comedications might affect the 
results. Thus, we adjusted for the differences in dementia between the ADS subgroups, but 
the adjusted models did not show significant decline in any of the cognitive test scores when 
the ADS score increased above 3. In addition, we controlled for the influence of comorbid 
depression and concurrent use of cholinesterase inhibitors due to the potential importance of 
these covariates on cognitive test scores, but this did not alter the results. However, the NPI 
recordings might have underestimated the prevalence of depression (< 5 %) which is 
supported by the fact that 50% of the residents were treated with antidepressants.
Furthermore, the high prevalence of cognitive impairment in our study population might have 
reduced the sensitivity of the anticholinergic drug burden on the cognitive test scores. This is 
consistent with two previous studies reporting no cognitive impact of high anticholinergic 
burden in old patients with dementia [6;27] However, the separate analyses of cognitively 
intact participants (CDR = 0; n = 27) in the present study did not show a greater decline in 
cognitive test performances than observed in the patients with dementia (CDR = 1-2; n = 60). 
Unfortunately, the small number of participants in each ADS subgroup limits the 
interpretation of these data. Nevertheless, among nursing home residents with no, mild or 
moderate dementia, the ADS score model appears to have a limited potential to predict the 
clinical risk of central anticholinergic side- effects.
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In addition to the cognitive tests included, we decided to measure activity of daily living 
(ADL). The inclusion of ADL was based on a small previous study reporting greater 
impairment in ADL in demented patients with high versus low anticholinergic burden [28].
Unfortunately, the validity of the current ADL registration is considered to be reduced 
because the registration forms for Barthel’s Index were filled in by 21 different caregivers 
with variable knowledge about the patients. However, we observed a significant increase in
ADL with increasing ADS score above 3, but the increase in ADL did not persist statistically 
significant after adjusting for the imbalance in CDR which indicates that the observed 
increase in ADL is explained by the absence of patients with moderate dementia in the group 
with the highest ADS scores.
In the present material, nursing home residents with dementia had significantly lower ADS 
scores than those without dementia. This observation might indicate that patients with 
dementia are prescribed less anticholinergic drugs than others, which is appropriate from a 
pharmacological point of view. However, whether the lower ADS score in patients with 
dementia was due to rational medical decisions, or simply reflected a generally restrictive 
prescription policy in this patient subgroup, is unclear. Nevertheless, as the 
pathophysiological changes in cholinergic brain transmission in Alzheimer’s dementia 
increase the sensitivity to temporary cholinergic blockade [24], it would be favorable to avoid 
or limit use of anticholinergic drugs in people with dementia.
Interestingly, we observed that the overall ADS score was significantly associated to 
peripheral anticholinergic end-points in terms of a 1.2-fold higher serum anticholinergic 
activity and 0.7-fold lower saliva production in subjects with ADS compared to those with 
ADS score 3. The significant increase in SAA and in peripheral, but not central adverse 
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effects demonstrated for subjects with ADS , might be understood in terms of how the 
ADS score model was developed. The potential anticholinergic effects of many drugs
included in the model were characterized by in vitro activity to muscarinic receptors measured 
by the same bio-assay as used for determination of SAA. The drugs were further graded as 
mild (ADS = 1), moderate (ADS = 2), or markedly anticholinergic (ADS = 3) based upon a 
consensus of clinical experience, previously reported adverse effects and knowledge of the
drugs’ properties. As symptoms of central anticholinergic side-effects may be subtle in 
patients with cognitive disorders (e.g. mild alterations in verbal short-time memory and 
attention), it’s possible that the model was primarily based upon symptoms of peripheral 
anticholinergic activity. 
The interpretation of the present results is restricted by the cross-sectional design and the 
relatively low and imbalanced number of patients in each ADS category. A randomized, 
controlled study investigating the potential improvement in cognitive function after an 
interventional reduction in ADS score would be more conclusive to clarify the clinical utility 
of the risk score model for evaluation of adverse drug effects. In similar with the validity 
restrictions of all prescription risk tools in the elderly, the external validity of the present 
results is limited by the great variability in drug response associated with advanced age, multi 
morbidity and polypharmacy. On the contrary, the prospective design and the consistent
findings within the cognitive and peripheral end-points strengthen the validity. The results are 
further strengthened by the fact that all cognitive measurements were performed by one study 
nurse who was blinded to the participants’ ADS scores.
In conclusion, the current study does not support a progressive decline in cognitive function 
with ADS scores above 3. Despite the relatively low number of participants included and 
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restrictions in the external validity, the findings might indicate that the ADS score model has 
limited potential to predict the clinical risk of central anticholinergic side-effects in frail 
elderly patients receiving multiple anticholinergic drugs. 
16
Conflict of Interest
All authors have completed the Unified Competing Interest form at 
www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and 
declare: HK had support from The South-Eastern Norway Regional Health and The 
Norwegian Directorate of Health Authority; no financial relationships with any organisations 
that might have an interest in the submitted work in the previous 3 years. 
Acknowledgements
We appreciate the excellent assistance of the study nurse, Inga Kristin Tolo, who performed 
all the clinical tests. We are thankful to the staff of the 21 different nursing homes and all the 
nursing home residents participating in this study. Finally, we thank Eva Skovlund and 
Haavard Aakre for their helpful assistance with the statistical data analysis. 
17
Reference List
1 Chew ML, Mulsant BH, Pollock BG; Lehman ME; Greenspan A; Mahmoud RA;
Kirshner MA; Sorisio DA; Bries RR; Gharabawi G.. Anticholinergic activity of 107 
medications commonly used by older adults. J.Am.Geriatr.Soc. 2008; 56: 1333-1341.
2 Campbell N, Boustani M, Limbil T; Ott H; Fox C; Maidment I; Scubert CC; Munger 
S; Flick D; Miller D; Gulati R. The cognitive impact of anticholinergics: a clinical 
review. Clin.Interv.Aging 2009; 4: 225-233.
3 Gnjidic D, Cumming RG, Le Couteur DG; Handelsman DJ; Naganathan V; Abernethy 
DR; Hilmer SN. Drug Burden Index and physical function in older Australian men.
Br.J.Clin.Pharmacol. 2009; 68: 97-105.
4 Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated 
with poor memory and executive function in older men. J Am Geriatr Soc 2008; 56:
2203-2210.
5 Peters NL. Snipping the thread of life. Antimuscarinic side effects of medications in 
the elderly. Arch.Intern.Med. 1989; 149: 2414-2420.
6 Kolanowski A, Fick DM, Campbell J, Litaker M, Boustani M. A preliminary study of 
anticholinergic burden and relationship to a quality of life indicator, engagement in 
activities, in nursing home residents with dementia. J.Am.Med.Dir.Assoc. 2009; 10:
252-257.
7 Tune LE, Strauss ME, Lew MF; Breitlingeer E; Coyle JT. Serum levels of 
anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. 
Am.J.Psychiatry 1982; 139: 1460-1462.
8 Carnahan RM, Lund BC, Perry PJ; Pollock BG; Culp KR. The Anticholinergic Drug 
Scale as a measure of drug-related anticholinergic burden: associations with serum 
anticholinergic activity. J.Clin.Pharmacol. 2006; 46: 1481-1486.
9 Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale 
and anticholinergic adverse effects in older persons. Arch.Intern.Med. 2008; 168: 508-
513.
10 Lechevallier-Michel N, Molimard M, Dartigues JF, Fabrigoule C, Fourrier-Reglat A. 
Drugs with anticholinergic properties and cognitive performance in the elderly: results 
from the PAQUID Study. Br.J.Clin.Pharmacol. 2005; 59: 143-151.
11 Ancelin ML, Artero S, Portet F, Dupuy AM, Touchon J, Ritchie K. Non-degenerative 
mild cognitive impairment in elderly people and use of anticholinergic drugs: 
longitudinal cohort study. BMJ 2006; 332: 455-459.
12 Marin DB, Flynn S, Mare M; Lantz M; Hsu MA; Laurans M; Paredes M; Shreve T; 
Zaklad GR; Mohs RC. Reliability and validity of a chronic care facility adaptation of 
the Clinical Dementia Rating scale. Int.J.Geriatr.Psychiatry 2001; 16: 745-750.
13 Williams MM, Roe CM, Morris JC. Stability of the Clinical Dementia Rating, 1979-
2007. Arch.Neurol. 2009; 66: 773-777.
18
14 Fillenbaum GG, van BG, Morris JC; Mohns RC; Mirra SS; Davis PC; Tariot PN; 
Silverman JM; Clark CM; Welsh-Bohmer KA; Heyman A. Consortium to Establish a 
Registry for Alzheimer's Disease (CERAD): the first twenty years. Alzheimer's 
dement. 2008; 4: 96-109.
15 Braekhus A, Laake K, Engedal K. The Mini-Mental State Examination: identifying 
the most efficient variables for detecting cognitive impairment in the elderly. 
J.Am.Geriatr.Soc. 1992; 40: 1139-1145.
16 Karrasch M, Sinerva E, Gronholm P, Rinne J, Laine M. CERAD test performances in 
amnestic mild cognitive impairment and Alzheimer's disease. Acta Neurol.Scand.
2005; 111: 172-179.
17 Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. Md.State Med.J.
1965; 14: 61-65.
18 Navazesh M, Christensen CM. A comparison of whole mouth resting and stimulated 
salivary measurement procedures. J.Dent.Res. 1982; 61: 1158-1162.
19 Tune L, Coyle JT. Serum levels of anticholinergic drugs in treatment of acute 
extrapyramidal side effects. Arch.Gen.Psychiatry 1980; 37: 293-297.
20 Jakobsen SM, Kersten H, Molden E. Evaluation of brain anticholinergic activities of 
urinary spasmolytic drugs using a high-throughput radio receptor bioassay. 
J.Am.Geriatr.Soc. 2011; 59: 501-505.
21 van Doorn C, Bogardus ST, Williams CS, Concato J, Towle VR, Inouye SK. Risk 
adjustment for older hospitalized persons: a comparison of two methods of data 
collection for the Charlson index. J.Clin.Epidemiol. 2001; 54: 694-701.
22 Selbaek G, Kirkevold O, Sommer OH. The reliability and validity of the Norwegian 
version of the Neuropsychiatric Inventory, nursing home version (NPI-NH). 
Int.Psychogeriatr. 2008; 20: 375-382.
23 National Kidney Foundation. http://www.kidney.org/professionals/tools/2010
24 Sunderland T, Tariot PN, Cohen RM; Weingartner H; Mueller EA; Murphy DL.
Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-
matched controls. A dose-response study. Arch.Gen.Psychiatry 1987; 44: 418-426.
25 Little JT, Broocks A, Martin A; Hill JL; Tune LE; Mack C ; Cantillon M; Molchan S; 
Murphy DL. Serotonergic modulation of anticholinergic effects on cognition and 
behavior in elderly humans. Psychopharmacology (Berl). 1995; 120: 280-288.
26 Ray PG, Meador KJ, Loring DW, Zamrini EW, Yang XH, Buccafusco JJ. Central 
anticholinergic hypersensitivity in aging. J.Geriatr.Psychiatry Neurol. 1992; 5: 72-77.
27 Fox C, Livingston G, Maidment ID, Coulton S; Smithard DG; Brustani M; Katona C.
The impact of anticholinergic burden in Alzheimer's dementia-the LASER-AD study. 
Age Ageing 2011; 40: 730-735.
19
28 Rovner BW, David A, Lucas-Blaustein MJ, Conklin B, Filipp L, Tune L. Self-care 
capacity and anticholinergic drug levels in nursing home patients. Am.J.Psychiatry
1988; 145: 107-109.
20
Table 1 Characteristics of the study cohort represented by the four strata with different 
anticholinergic drug scale (ADS) score. 
Data represents median, interquartile range (IQR) and range or frequency and percentages 
within the stratum; n gives the valid data for each characteristics; a)Calculated by the 
Modification of Diet in Renal Disease (MDRD) formula; CDR = Clinical Dementia 
Rate.*Significant different distribution across the ADS subgroups, p < 0.05, Kruskal-Wallis 
test.
Characteristics ADS = 3
n = 36
ADS = 4
n = 22
ADS = 5
n = 16
ADS 
n = 13
Age 87 (84-93)
73-99
85 (83-87)
77-93
84 (81-91)
74-96
83 (81-90)
77-93
Female gender 29 (81%) 16 (73%) 13 (81%) 11(85%)
Education > 12 years 4 (11%) 2 (9%) 1 (6%) 0
Daily smoking 5 (14%) 3 (14%) 1 (6%) 4 (31%)
No dental prostheses 16 (44%) 11 (50%) 7 (44%) 4 (31%)
CDR*
0 = no dementia, n (%) 8 (22%) 5 (23%) 5 (31%) 9 (69%)
1 = mild dementia, n (%) 17 (47%) 8 (36%) 7 (44%) 4 (31%)
2 = moderate dementia, n (%) 11 (31%) 9 (41%) 4 (25%) 0
Scheduled drugs* 8 (6-10)
1-18
9 (7-10)
4-16
10.5 (8-13)
5-14
12 (9.5-5.5)
7-17
a)Glomerular Filtration Rate 69 (54-84.5)
33-207
72 (46-87)
18-125
72 (82.5-87)
38-147
55 (41-77)
24-129
Charlson Co-morbidity score 3.5 (3-4)
1-6
4 (2-6)
1-9
3 (2.5-5)
1-9
3 (3-5)
2-7
No. of participants using 
Cholinesterase inhibitors
1 1 1 1
Prevalence of clinical significant 
symptoms of depression (Fx I) LQ
neuropsychiatric inventory (NPI)
1 2 1
21
Table 2 Drugs with anticholinergic properties ranked by modified anticholinergic drug 
scale (ADS) within the study population, n = 87.
Frequency represent the number of participants exposed to drugs in present therapeutic 
group;*number of participants using at least one drug in present ADS category. (Several 
patients used more than one drug in each category)
Therapeutic
drug group
Frequency 
(% of n) 
Drug name
ADS = 3
62 (71.3%)*
ADS =2
10 (10.3%)*
ADS = 1
67 (77.0%)*
Antidepressants 44 (50.6) amitriptyline   
trimipramine
noritriptyline 
paroxetine
escitalopram  
citalopram   
mirtazapine       
fluoxetine
Antipsychotics 24 (276) chlorprothixene   
levomepromazine
olanzapine              quetiapine               
zuclopenthixol
High-ceiling diuretics 27 (31.0) furosemide
Antihistamines for 
systemic use
31 (35.6) hydroxyzine
alimemazine       
dexchlorpheninamine 
promethazine
Opioids 14 (16.1) fentanyl                     
oxycodone
Glucocorticoids 14 (16.1) prednisolone
Drugs for obstructive 
airway disease, inhalant 
and systemic use
14 (16.1) theophylline              
ipatropiumbromide
Cardiac glycosides 13 (14.9) digitoxin
Urinary spasmolytics 12 (13.8) tolterodine             
solifenacine
Anxiolytics 3 (3.4) diazepam
Antiepileptics 3 (3.4) oxcarbazepine
H2-receptor antagonists 2 (2.3) ranitidine
ACE inhibitors 2 (2.3) captopril
Lincosamides 1 (1.1) clindamycin
Total drug prevalence 204 65 10 129
22T
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Figure 1   Selection of study population
ADS = Anticholinergic Drug Scale  
CDR = Clinical Dementia Rating Scale
Screening of 1101 medical records
226 patients with ADS score 
139 not included:
44 with CDR = 3
40 physically incapable of 
executing the tests 
36 did not consent
12 kin did not consent
4 died
3 movedParticipants (n = 87) with 
ADS score DQG&'5
871 with ADS score < 3
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